title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,https://www.globenewswire.com/news-release/2024/01/24/2816080/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-01-24 21:10:00,"FARMINGTON HILLS, Mich., Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today ...",VTRS,0.05234,0.043,Neutral
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/24/01/g36767751/ocuphire-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4,2024-01-24 21:10:00,"FARMINGTON HILLS, Mich., Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc.",VTRS,0.051441,0.039992,Neutral
Elite investor David Einhorn warns of bubble-level hype around the hottest stocks - and teases a mystery bet,https://markets.businessinsider.com/news/stocks/einhorn-greenlight-tech-stock-bubble-mystery-position-geopolitics-investor-letter-2024-1,2024-01-23 14:18:00,"Einhorn Warns of Bubble-Level Stock Hype, Teases Mystery Bet - Markets Insider ...",VTRS,0.104228,0.023425,Neutral
 ( VTRS )  - Analyzing Viatris's Short Interest - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/insights/short-sellers/24/01/36737104/vtrs-analyzing-viatriss-short-interest,2024-01-23 14:00:18,"Viatris's VTRS short percent of float has fallen 12.08% since its last report. The company recently reported that it has 30.47 million shares sold short, which is 2.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.83 days to cover ...",VTRS,0.224903,0.085754,Neutral
"Metered Dose Inhalers Market Forecast a Steady Growth at 4.9% CAGR, Projected to Hit US$39.4 Billion by 2030 | Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36732207/metered-dose-inhalers-market-forecast-a-steady-growth-at-4-9-cagr-projected-to-hit-us-39-4-billion,2024-01-23 08:45:00,"New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Metered Dose Inhalers Market Overview: The metered dose inhalers ( MDIs ) market has witnessed substantial growth and innovation in recent years, driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive ...",VTRS,0.041731,0.135577,Neutral
"Cold Relief Roll-On Market Projected to Surge at 8.7% CAGR, Reaching US$926.7 Million by 2030, Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36718944/cold-relief-roll-on-market-projected-to-surge-at-8-7-cagr-reaching-us-926-7-million-by-2030-persis,2024-01-22 16:15:00,"New York, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- The dynamic cold relief roll-on market operates within the broader healthcare and wellness industry, providing a convenient and targeted remedy for individuals seeking relief from cold symptoms.",VTRS,0.020249,0.21944,Somewhat-Bullish
"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html,2024-01-22 04:35:00,"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",VTRS,0.049939,0.083583,Neutral
2 Smart Growth Stocks to Buy Hand Over Fist in 2024,https://www.fool.com/investing/2024/01/21/2-smart-growth-stocks-to-buy-hand-over-fist/,2024-01-21 12:15:00,These businesses are on paths to extremely bright futures.,VTRS,0.039548,0.041695,Neutral
"Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva Pharma, 3M Company, Nitto Denko Corporation, and Johnson & Johnson",https://www.prnewswire.com/news-releases/global-transdermal-skin-patches-market-forecast-report-2024-2030-a-9-9b-projected-industry-dominated-by-teva-pharma-3m-company-nitto-denko-corporation-and-johnson--johnson-302039341.html,2024-01-19 17:15:00,"Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva ... PR ...",VTRS,0.031738,0.121467,Neutral
Charts turn bullish on health-care stocks as sector takes early lead in 2024,https://www.marketwatch.com/story/charts-turn-bullish-on-health-care-stocks-as-sector-takes-early-lead-in-2024-12272495,2024-01-16 16:29:00,"Health-care stocks are off to a strong start in 2024, and Wall Street analysts are taking notice.",VTRS,0.15697,0.0,Neutral
Allergy Immunotherapies Market to grow by USD 1.01 billion from 2022 to 2027; Europe to account for 53% of market ... - PR Newswire,https://www.prnewswire.com/news-releases/allergy-immunotherapies-market-to-grow-by-usd-1-01-billion-from-2022-to-2027-europe-to-account-for-53-of-market-growth---technavio-302034465.html,2024-01-16 02:15:00,Allergy Immunotherapies Market to grow by USD 1.01 billion from 2022 to 2027. Europe to account for 53% of market ... PR ...,VTRS,0.049424,0.03685,Neutral
These 9 Stocks Are Running To Start 2024,https://www.investors.com/news/sp-500-these-9-stocks-are-running-to-start-2024/,2024-01-14 13:00:00,"The S&P 500 index is up just a fraction in 2024 so far, but a number of big caps are off to a strong start. Nvidia ( NVDA ) , the No. 1 S&P 500 stock performer in 2023, is leading the way again. That is, excluding Juniper Networks ( JNPR ) , which spiked last week as Hewlett Packard Enterprise ( ...",VTRS,0.264515,0.098631,Neutral
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36611580/regeneron-pharmas-pipeline-makes-this-analyst-turn-bullish,2024-01-12 15:18:10,"Regeneron Pharmaceuticals Inc REGN won a lawsuit last month against Viatris Inc VTRS over its Eylea patent. While the performance of the company's Dupixent treatment is likely to be strong in the near term, chronic obstructive pulmonary disease ( COPD ) is likely to offer ""a meaningful ...",VTRS,0.320974,0.242787,Somewhat-Bullish
Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts,https://markets.businessinsider.com/news/stocks/beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-street-s-most-accurate-analysts-1032963710,2024-01-12 13:26:27,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",VTRS,0.112008,0.020144,Neutral
"Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts - Organon  ( NYSE:OGN ) , Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/news/24/01/36609836/beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-mo,2024-01-12 13:26:26,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",VTRS,0.112008,0.170225,Somewhat-Bullish
60% Of This Year's Top Stocks Are In This Sector  ( It's Not Tech ) ,https://www.investors.com/etfs-and-funds/etfs/sp500-this-years-top-stocks-are-in-this-sector-not-tech/,2024-01-11 13:00:00,"Just when it looked like technology stocks took over the S&P 500 - another sector is on the rise. Health care stocks, like Viatris ( VTRS ) , Catalent ( CTLT ) and Moderna ( MRNA ) , are dominating the ranks of top-performing stocks this year so far, says an Investor's Business Daily analysis of ...",VTRS,0.243498,0.201769,Somewhat-Bullish
Here's Why You Should Invest in Ocuphire Pharma  ( OCUP )  Now,https://www.zacks.com/stock/news/2208705/heres-why-you-should-invest-in-ocuphire-pharma-ocup-now,2024-01-11 12:41:00,"Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.",VTRS,0.34648,0.18715,Somewhat-Bullish
Stocks With Rising Relative Price Strength: Viatris,https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-viatris/,2024-01-11 08:00:00,"On Thursday, Viatris ( VTRS ) received an upgrade to its Relative Strength ( RS ) Rating, from 78 to 84. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",VTRS,0.524949,0.396901,Bullish
Unichem Laboratories hit 52-week high on USFDA nod for hypertension drug,https://www.moneycontrol.com/news/business/stocks/unichem-laboratories-hit-52-week-high-on-usfda-nod-for-hypertension-drug-12033501.html,2024-01-11 06:51:17,"The company will manufacture doxazosin tablets, a generic version of Cardura of Viatris Specialty, at its Goa plant ...",VTRS,0.195814,0.161238,Somewhat-Bullish
"Epinephrine Autoinjector Market size to grow by USD 2.44 billion from 2023 to 2028, North America to account for 46 ... - PR Newswire",https://www.prnewswire.com/news-releases/epinephrine-autoinjector-market-size-to-grow-by-usd-2-44-billion-from-2023-to-2028--north-america-to-account-for-46-of-market-growth--technavio-302027156.html,2024-01-07 22:15:00,"Epinephrine Autoinjector Market size to grow by USD 2.44 billion from 2023 to 2028, North America to account for 46 ... PR ...",VTRS,0.051999,0.0,Neutral
"Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... - PR Newswire",https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-is-to-grow-by-usd-86-47-billion-from-2023-to-2028--asia-to-account-for-52-of-market-growth---technavio-302026179.html,2024-01-05 22:01:00,"Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... PR ...",VTRS,0.06623,0.0,Neutral
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? - Theravance Biopharma  ( NASDAQ:TBPH ) ,https://www.benzinga.com/general/biotech/24/01/36508164/why-is-lung-disease-focused-theravance-biopharma-stock-trading-lower-today,2024-01-05 15:36:54,"Theravance Biopharma Inc TBPH announced results from the Phase 4 PIFR-2 study of Yupelri ( revefenacin ) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist ( LAMA ) approved in the U.S. for maintenance treatment of chronic obstructive pulmonary disorder ( COPD ...",VTRS,0.334762,0.182645,Somewhat-Bullish
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024,https://www.zacks.com/stock/news/2206307/3-top-biotech-stocks-worth-adding-to-your-portfolio-in-2024,2024-01-05 14:49:00,"REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.",VTRS,0.054607,0.13707,Neutral
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim  ( mesopic )  Light Conditions,https://www.globenewswire.com/news-release/2024/01/04/2803925/0/en/Ocuphire-Pharma-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-for-LYNX-2-Phase-3-Trial-of-Phentolamine-Ophthalmic-Solution-for-the-Treatment-of-Decreased-Visual-Acuity-u.html,2024-01-04 13:00:00,"Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024 Phase 3 Startup Activities are Underway, with Trial Initiation Expected in ...",VTRS,0.086039,0.041896,Neutral
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim  ( mesopic )  Light Conditions - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/24/01/g36488012/ocuphire-pharma-receives-fda-agreement-under-special-protocol-assessment-for-lynx-2-phase-3-trial-,2024-01-04 13:00:00,"FARMINGTON HILLS, Mich., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced it has ...",VTRS,0.085223,0.039668,Neutral
Regeneron  ( REGN )  Surges 3.0%: Is This an Indication of Further Gains?,https://www.zacks.com/stock/news/2205086/regeneron-regn-surges-30-is-this-an-indication-of-further-gains,2024-01-03 15:32:00,Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.,VTRS,0.112532,0.209253,Somewhat-Bullish
"VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/24/01/g36445581/viatris-alert-bragar-eagel-squire-p-c-is-investigating-viatris-inc-on-behalf-of-long-term-stockhol,2024-01-02 02:00:00,"NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc.",VTRS,0.774534,-0.137863,Neutral
"Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Lower Premarket Today? - Viatris  ( NASDAQ:VTRS ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/12/36408741/regeneron-celebrates-legal-win-court-upholds-eylea-medication-patent,2023-12-28 13:46:57,"Wednesday, a court ruling that found Viatris Inc's VTRS replica of Regeneron Pharmaceuticals Inc's REGN eye drug, Eylea ( aflibercept ) , violated patent rights. The decision from the U.S.",VTRS,0.56296,0.0,Neutral
"3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts - CVS Health  ( NYSE:CVS ) , Organon  ( NYSE:OGN ) ",https://www.benzinga.com/news/23/12/36395654/3-minutes-to-boost-your-earnings-3-stocks-with-over-3-dividend-yields-in-health-care-sector-from-wal,2023-12-27 12:42:08,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",VTRS,0.104683,0.110976,Neutral
Gainers & Losers: 10 stocks that moved the most on December 26,https://www.moneycontrol.com/news/photos/business/stocks/gainers-losers-10-stocks-that-moved-the-most-on-december-26-2-11957671.html,2023-12-26 11:11:33,"About 2,234 shares advanced, 1,506 shares declined, and 139 shares remained unchanged on December ...",VTRS,0.036255,0.16967,Somewhat-Bullish
Biocon shares gain on immunity jab distribution deal with Sandoz for Japan,https://www.moneycontrol.com/news/business/stocks/biocon-shares-gain-on-immunity-jab-distribution-deal-with-sandoz-for-japan-11951471.html,2023-12-26 04:11:57,"Biocon Biologics signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS for subcutaneous injection.",VTRS,0.462395,0.361619,Bullish
"Buzzing Stocks: Reliance, Adani Wilmar, Tata Steel, Infosys, Adani Power, others in news",https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-reliance-adani-wilmar-tata-steel-infosys-adani-power-others-in-news-11953941.html,2023-12-26 00:53:38,"Stocks to watch: Check out the companies making headlines before the opening bell today, on December 26, 2023.",VTRS,0.058903,0.119054,Neutral
"A Look Into Healthcare Sector Value Stocks - Kiora Pharmaceuticals  ( NASDAQ:KPRX ) , BioNTech  ( NASDAQ:BNTX ) ",https://www.benzinga.com/news/23/12/36378877/a-look-into-healthcare-sector-value-stocks,2023-12-25 14:43:43,A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.,VTRS,0.185306,0.276601,Somewhat-Bullish
"Biocon arm, Sandoz to distribute rheumatoid arthritis drug in Japan",https://www.business-standard.com/companies/news/biocon-arm-sandoz-to-distribute-rheumatoid-arthritis-drug-in-japan-123122200794_1.html,2023-12-22 12:25:27,"Biocon arm Biocon Biologics Ltd ( BBL ) has partnered with Sandoz for the distribution, sale, and promotion of Adalimumab ( a biosimilar version of the blockbuster drug Humira ) in Japan. Adalimumab is indicated for rheumatoid arthritis.",VTRS,0.451494,0.426967,Bullish
"Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-announces-appointment-of-jeremy-grant-to-board-of-directors-302021352.html,2023-12-21 22:00:00,"Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ( ""Theravance"" or the ""Company"" ) ( NASDAQ: TBPH ) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special ...",VTRS,0.029078,0.07201,Neutral
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,https://www.zacks.com/stock/news/2199901/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now,2023-12-19 13:50:02,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,VTRS,0.376194,0.351446,Bullish
Biocon falls even after subsidiary completes biosimilar integration before schedule,https://www.moneycontrol.com/news/business/markets/biocon-falls-even-after-subsidiary-completes-biosimilar-integration-before-schedule-11926151.html,2023-12-19 07:10:10,Biocon Biologics acquired all the global biosimilar businesses of Viatris in November 2022.,VTRS,0.308891,0.10724,Neutral
Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries,https://www.moneycontrol.com/news/business/markets/biocon-biologics-completes-integration-of-viatris-biosimilar-business-in-120-countries-11922921.html,2023-12-18 16:26:34,"Earlier in 2023, the integration process included over 70 emerging markets in July, the North America business in September, and the European business in November ...",VTRS,0.186738,0.130698,Neutral
Biocon Biologics completes integration of Viatris' biosimilars business,https://www.business-standard.com/companies/news/biocon-biologics-completes-integration-of-viatris-biosimilars-business-123121800822_1.html,2023-12-18 12:48:33,"Biocon Biologics, a subsidiary of Biocon, has announced the successful completion of the integration of the acquired biosimilars business across approximately 120 countries, a year ahead of schedule.",VTRS,0.090474,0.089181,Neutral
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries,https://www.prnewswire.com/apac/news-releases/biocon-biologics-concludes-integration-of-acquired-biosimilars-business-in-120-countries-302017799.html,2023-12-18 12:44:00,"KUALA LUMPUR, Malaysia, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition ...",VTRS,0.19661,0.132734,Neutral
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries,https://www.prnewswire.com/news-releases/biocon-biologics-concludes-integration-of-acquired-biosimilars-business-in-120-countries-302017727.html,2023-12-18 11:14:00,"DUBAI, UAE, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ ...",VTRS,0.197413,0.133142,Neutral
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference,https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-42nd-annual-healthcare-conference-302017596.html,2023-12-18 11:00:00,"DUBLIN, Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ( ""Theravance Biopharma"" or the ""Company"" ) ( NASDAQ: TBPH ) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P.",VTRS,0.159569,0.102734,Neutral
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora ... - PR Newswire,https://www.prnewswire.com/news-releases/viatris-continues-its-preparations-for-phase-2-of-its-strategic-plan-by-announcing-the-appointment-of-theodora-doretta-mistras-as-chief-financial-officer-effective-march-1-2024-and-philippe-martin-as-chief-rd-officer-302017098.html,2023-12-15 21:45:00,Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora ... PR ...,VTRS,0.696068,0.48508,Bullish
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders - PR Newswire,https://www.prnewswire.com/news-releases/viatris-shareholders-re-elect-all-nominated-directors-and-approve-all-voting-matters-at-annual-meeting-of-shareholders-302017018.html,2023-12-15 21:05:00,Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders PR ...,VTRS,0.750264,0.303852,Somewhat-Bullish
Investing half a billion dollar in our generics business: Biocon MD & CEO,https://www.business-standard.com/companies/interviews/investing-half-a-billion-dollar-in-our-generics-business-biocon-md-ceo-123121500948_1.html,2023-12-15 15:20:57,"Customer demand for generics has moderated due to inventories stocking up. Bengaluru-headquartered biotech major Biocon has been working to reduce its cumulative debt of around $1.5 billion, of which around $1.2 billion was taken to fund the acquisition of Viatris' biosimilars business.",VTRS,0.310843,-0.011456,Neutral
No plan to divest any part of the generics business: Biocon MD & CEO,https://www.business-standard.com/companies/interviews/we-are-investing-half-a-billion-dollars-in-generics-biz-biocon-md-ceo-123121500948_1.html,2023-12-15 15:20:05,"Customer demand for generics has moderated due to inventories stocking up. Bengaluru-headquartered biotech major Biocon has been working to reduce its cumulative debt of around $1.5 billion, of which around $1.2 billion was taken to fund the acquisition of Viatris' biosimilars business.",VTRS,0.310843,-0.011456,Neutral
Biocon considers selling generic API biz; turn into biosimilar major,https://www.business-standard.com/companies/news/biocon-considers-selling-generic-api-biz-turn-into-biosimilar-major-123121500174_1.html,2023-12-15 04:15:42,Biocon considers selling generic API biz. turn into biosimilar major Business Standard ...,VTRS,0.121037,-0.004615,Neutral
Vertex's stock heads for all-time high as non-opioid painkiller shows promise,https://www.marketwatch.com/story/vertexs-stock-heads-for-all-time-high-as-non-opioid-painkiller-shows-promise-3a42c530,2023-12-13 17:03:00,Vertex Pharmaceuticals' stock was on track for an all-time high Wednesday after the company released new data on its experimental non-opioid pain medicine.,VTRS,0.252987,0.0,Neutral
Transdermal Patches Market is Expected to Reach $8.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/23/12/g36151396/transdermal-patches-market-is-expected-to-reach-8-0-billion-marketsandmarkets,2023-12-08 12:30:00,"Chicago, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- Transdermal Patches market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $8.0 billion by 2029, growing at a CAGR of 4.5% from 2023 to 2029 according to a latest report published by MarketsandMarkets™.",VTRS,0.031529,0.006513,Neutral
Viatris  ( VTRS )  Up 5.1% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2194907/viatris-vtrs-up-51-since-last-earnings-report-can-it-continue,2023-12-07 16:31:07,Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.551119,0.325395,Somewhat-Bullish
Theravance Bio  ( TBPH )  Up 2.5% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2194974/theravance-bio-tbph-up-25-since-last-earnings-report-can-it-continue,2023-12-07 16:30:57,Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.065327,0.067067,Neutral
India Inc still big on foreign loans despite high US rates - ETCFO,https://cfo.economictimes.indiatimes.com/news/corporate-finance/india-inc-still-big-on-foreign-loans-despite-high-us-rates/105770034,2023-12-06 03:23:11,"Indian companies are set to borrow more than $25 billion abroad this year, trumping the $19 billion raised in 2022, according to a top HSBC executive. The UK-headquartered bank has emerged as the No. 1arranger of foreign currency loans this year across league tables.",VTRS,0.072435,0.082519,Neutral
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... - PR Newswire,https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-size-to-grow-by-usd-65-13-billion-from-2022-2027-aquestive-therapeutics-inc-bausch-health-companies-inc-biogen-inc-and-more-among-the-major-companies-in-the-market--technavio-302002042.html,2023-12-01 18:30:00,Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... PR ...,VTRS,0.059636,0.014995,Neutral
Biocon Biologics integrates Viatris' biosimilar biz in 31 European nations,https://www.business-standard.com/companies/news/biocon-biologics-integrates-viatris-biosimilar-biz-in-31-european-nations-123113000741_1.html,2023-11-30 18:01:45,Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European countries.,VTRS,0.666827,0.257637,Somewhat-Bullish
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit  ( OIS )  XIII,https://www.globenewswire.com/news-release/2023/11/30/2788530/0/en/Ocuphire-Pharma-Announces-Presentation-at-Ophthalmology-Innovation-Summit-OIS-XIII.html,2023-11-30 13:00:00,"Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023 Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December ...",VTRS,0.035983,0.040343,Neutral
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit  ( OIS )  XIII - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/23/11/g36020837/ocuphire-pharma-announces-presentation-at-ophthalmology-innovation-summit-ois-xiii,2023-11-30 13:00:00,"FARMINGTON HILLS, Mich., Nov. 30, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc.",VTRS,0.035293,0.037244,Neutral
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe,https://www.prnewswire.com/in/news-releases/biocon-biologics-successfully-completes-integration-of-viatris-biosimilar-business-in-31-countries-in-europe-302001922.html,2023-11-30 11:07:00,"BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd ( BBL ) , a subsidiary of Biocon Ltd ( BSE code: 532523, NSE: BIOCON ) , today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed.",VTRS,0.242084,0.209543,Somewhat-Bullish
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe,https://www.prnewswire.com/news-releases/biocon-biologics-successfully-completes-integration-of-viatris-biosimilar-business-in-31-countries-in-europe-302001903.html,2023-11-30 10:47:00,"BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd ( BBL ) , a subsidiary of Biocon Ltd ( BSE code: 532523, NSE: BIOCON ) , today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed.",VTRS,0.242084,0.209543,Somewhat-Bullish
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe,https://www.newswire.ca/news-releases/biocon-biologics-successfully-completes-integration-of-viatris-biosimilar-business-in-31-countries-in-europe-885578092.html,2023-11-30 10:47:00,"BENGALURU, India, Nov. 30, 2023 /CNW/ -- Biocon Biologics Ltd ( BBL ) , a subsidiary of Biocon Ltd ( BSE code: 532523, NSE: BIOCON ) , today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed.",VTRS,0.22595,0.198506,Somewhat-Bullish
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,https://www.globenewswire.com/news-release/2023/11/27/2786540/0/en/Ocuphire-Pharma-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2023-11-27 21:38:00,"FARMINGTON HILLS, Mich., Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today ...",VTRS,0.034136,0.04015,Neutral
Biocon bets big on new class of weight-loss drugs,https://www.moneycontrol.com/news/business/stocks/biocon-bets-big-on-new-class-of-weight-loss-drugs-11805641.html,2023-11-24 07:16:39,Company aims to ramp up portfolio as key drugs-that were actually formulated to treat diabetes-go off patent ...,VTRS,0.06211,0.228248,Somewhat-Bullish
Is First Trust Health Care AlphaDEX ETF  ( FXH )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2186427/is-first-trust-health-care-alphadex-etf-fxh-a-strong-etf-right-now,2023-11-20 11:20:06,Smart Beta ETF report for ...,VTRS,0.119235,0.0608,Neutral
VTRS: Under $15 Bargains: 3 Pharma Stocks to Watch,https://stocknews.com/news/vtrs-ogn-gdrx-under-15-bargains-3-pharma-stocks-to-watch/,2023-11-17 12:44:17,"The pharmaceutical sector stands on the precipice of significant growth, driven by a rapidly burgeoning market for medications and vaccines. Additionally, this sector's sustained product demands underscore its resilience, making it less susceptible to economic volatility.",VTRS,0.33433,0.108007,Neutral
Should You Invest in the First Trust Health Care AlphaDEX ETF  ( FXH ) ?,https://www.zacks.com/stock/news/2184363/should-you-invest-in-the-first-trust-health-care-alphadex-etf-fxh,2023-11-15 11:20:04,Sector ETF report for ...,VTRS,0.132004,0.070801,Neutral
U.S. Pruritus Treatment Market to Hit USD 8.4 billion by 2031 | Says Transparency Market Research Inc.,https://www.benzinga.com/pressreleases/23/11/g35784459/u-s-pruritus-treatment-market-to-hit-usd-8-4-billion-by-2031-says-transparency-market-research-inc,2023-11-14 18:00:00,"Wilmington, Delaware, United States, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global U.S. pruritus treatment market was estimated at a value of US$ 5.1 billion in 2022. It is anticipated to register a 5.6% CAGR from 2023 to 2031 and by 2031.",VTRS,0.03798,0.0,Neutral
Biocon aims to become a top three biosimilar players in world: Tambe,https://www.business-standard.com/companies/interviews/biocon-aims-to-become-a-top-three-biosimilar-players-in-world-tambe-123111300860_1.html,2023-11-13 15:52:29,Biocon Biologics targets top three biosimilar spot: Shreehas Tambe Business Standard ...,VTRS,0.546745,0.408229,Bullish
"5 Value Stocks To Watch In The Healthcare Sector - Cross Country Healthcare  ( NASDAQ:CCRN ) , Adial Pharmaceuticals  ( NASDAQ:ADIL ) ",https://www.benzinga.com/news/23/11/35750975/5-value-stocks-to-watch-in-the-healthcare-sector,2023-11-13 14:44:40,A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.,VTRS,0.197413,0.204904,Somewhat-Bullish
Biosimilars growth pushes Biocon Q2 PAT rises 168% to Rs 126 crore,https://www.business-standard.com/companies/results/biocon-q2-results-net-profit-zooms-over-two-fold-revenue-up-49-123111000947_1.html,2023-11-10 13:02:20,"Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics stated, 'Biocon reported strong revenue growth this quarter, largely by a revenue rise of 97 per cent in Biosimilars.",VTRS,0.178459,0.259881,Somewhat-Bullish
Biocon Q2 results: Net profit more than doubles to Rs 172.7 crore,https://www.moneycontrol.com/news/business/earnings/biocon-q2-results-net-profit-more-than-doubles-to-rs-172-7-crore-11713971.html,2023-11-10 11:11:43,Biocon Q2 earnings: The company reported a profit of Rs 414.5crore in the same period of the previous year ...,VTRS,0.227007,0.290841,Somewhat-Bullish
Teva Pharmaceutical Industries  ( TEVA )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/11/08/teva-pharmaceutical-industries-teva-q3-2023-earnin/,2023-11-08 19:15:17,"TEVA earnings call for the period ending September 30, 2023.",VTRS,0.004675,0.081541,Neutral
"Viatris  ( VTRS )  Q3 Earnings Beat, Complex Generics Sales Dip",https://www.zacks.com/stock/news/2181070/viatris-vtrs-q3-earnings-beat-complex-generics-sales-dip,2023-11-08 17:17:00,"Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.",VTRS,0.662687,0.229634,Somewhat-Bullish
"Theravance's  ( TBPH )  Q3 Loss Narrows, Revenues Beat Marginally",https://www.zacks.com/stock/news/2181005/theravances-tbph-q3-loss-narrows-revenues-beat-marginally,2023-11-08 16:35:00,Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.,VTRS,0.443626,0.282932,Somewhat-Bullish
Viatris  ( VTRS )  Beats Q3 Earnings Estimates,https://www.zacks.com/stock/news/2180367/viatris-vtrs-beats-q3-earnings-estimates,2023-11-07 22:25:07,"Viatris (VTRS) delivered earnings and revenue surprises of 5.41% and 1.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.400265,0.119427,Neutral
"Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-third-quarter-2023-financial-results-and-provides-business-update-301980723.html,2023-11-07 21:28:00,"DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ( ""Theravance Biopharma"" or the ""Company"" ) ( NASDAQ: TBPH ) today announced financial and operational results for the third quarter of 2023.",VTRS,0.14947,0.101941,Neutral
Should You Buy Viatris  ( VTRS )  Ahead of Earnings?,https://www.zacks.com/stock/news/2179339/should-you-buy-viatris-vtrs-ahead-of-earnings,2023-11-06 15:47:00,Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,VTRS,0.904419,0.60567,Bullish
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,https://www.zacks.com/stock/news/2179051/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now,2023-11-06 13:50:06,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,VTRS,0.323078,0.298294,Somewhat-Bullish
"Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More",https://www.zacks.com/stock/news/2179006/biotechdrug-stocks-q3-earnings-due-nov-7-gild-prgo-vtrs-more,2023-11-06 13:26:00,"Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.",VTRS,0.252612,0.089265,Neutral
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/23/11/g35560717/ocuphire-pharma-announces-successful-end-of-phase-2-meeting-with-fda-for-oral-apx3330-in-diabetic-,2023-11-02 12:00:00,Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale ( DRSS ) Score Company Plans to Submit a Special Protocol Assessment ( SPA ) APX3330 has the Potential to be the First Oral Option for 8M Non-Proliferative Diabetic Retinopathy ( ...,VTRS,0.052169,0.029,Neutral
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/23/11/g35550863/ocuphire-pharma-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4,2023-11-01 20:52:46,"FARMINGTON HILLS, Mich., Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc.",VTRS,0.033846,0.017526,Neutral
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,https://www.globenewswire.com/news-release/2023/11/01/2771776/0/en/Ocuphire-Pharma-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2023-11-01 20:52:00,"FARMINGTON HILLS, Mich., Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today ...",VTRS,0.034233,0.019555,Neutral
"Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director",https://www.globenewswire.com/news-release/2023/11/01/2771141/0/en/Ocuphire-Pharma-Announces-Appointment-of-George-Magrath-M-D-M-B-A-M-S-as-Chief-Executive-Officer-and-Director.html,2023-11-01 12:05:00,"Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development ...",VTRS,0.059415,0.160321,Somewhat-Bullish
Viatris  ( VTRS )  to Report Q3 Earnings: Is a Beat in Store?,https://www.zacks.com/stock/news/2175750/viatris-vtrs-to-report-q3-earnings-is-a-beat-in-store,2023-10-31 15:17:00,Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.,VTRS,0.567965,0.300198,Somewhat-Bullish
Viatris  ( VTRS )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,https://www.zacks.com/stock/news/2175498/viatris-vtrs-expected-to-beat-earnings-estimates-can-the-stock-move-higher,2023-10-31 14:01:40,Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,VTRS,0.260652,0.146366,Neutral
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?,https://www.fool.com/investing/2023/10/31/ozempic-just-shrugged-off-a-challenge-from-viatris/,2023-10-31 09:05:00,Viatris now faces a narrower path to commercializing a generic copy of Ozempic.,VTRS,0.613172,0.050504,Neutral
Why Viatris  ( VTRS )  is Poised to Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2174723/why-viatris-vtrs-is-poised-to-beat-earnings-estimates-again,2023-10-30 16:10:10,Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,VTRS,0.410505,0.488996,Bullish
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,https://www.zacks.com/stock/news/2174322/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now,2023-10-30 12:50:14,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,VTRS,0.374312,0.352546,Bullish
Transdermal Drug Delivery System Market to Hit 4.3% CAGR with Transdermal Gels Segment Driving Growth During 2022-2030 | The Insight Partners,https://www.benzinga.com/pressreleases/23/10/g35417362/transdermal-drug-delivery-system-market-to-hit-4-3-cagr-with-transdermal-gels-segment-driving-grow,2023-10-25 14:40:15,"Pune, India, Oct. 25, 2023 ( GLOBE NEWSWIRE ) -- Transdermal drug delivery systems are dosage forms actively used to deliver a therapeutically effective amount of drug across a patient's skin.",VTRS,0.025817,0.061488,Neutral
Biocon Biologics appoints Kedar Upadhye as new chief financial officer,https://www.business-standard.com/companies/people/biocon-biologics-appoints-kedar-upadhye-as-new-chief-financial-officer-123101900691_1.html,2023-10-19 10:42:20,"Former Cipla global chief financial officer ( CFO ) Kedar Upadhye is appointed as the new CFO of Biocon Biologics. Current CFO, MB Chinappa will take on a strategic finance role at Biocon Group. These leadership changes will be effective October 31, 2023.",VTRS,0.181819,0.215051,Somewhat-Bullish
Biocon Biologics appoints Kedar Upadhye as new Chief Financial Officer,https://www.financialexpress.com/healthcare/news-healthcare/biocon-biologics-appoints-kedar-upadhye-as-new-chief-financial-officer/3279189/,2023-10-19 10:16:39,"Biocon Biologics Ltd ( BBL ) on Wednesday announced that the Board of Directors of Biocon Biologics have appointed Kedar Upadhye as the new Chief Financial Officer ( CFO ) and the Company's current CFO, MB Chinappa, will transition to take on a strategic finance role at Biocon Group.",VTRS,0.121037,0.27923,Somewhat-Bullish
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics,https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html,2023-10-13 15:45:00,Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...,VTRS,0.036643,0.067285,Neutral
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?,https://www.fool.com/investing/2023/10/13/viatris-just-sold-off-3-key-segments-is-it-still-a/,2023-10-13 13:15:00,There's a chance shareholders won't notice any difference.,VTRS,0.480536,0.324812,Somewhat-Bullish
2 Top Value Stocks to Buy in October,https://www.fool.com/investing/2023/10/08/2-top-value-stocks-to-buy-in-october/,2023-10-08 13:45:00,"These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects.",VTRS,0.481677,0.435117,Bullish
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip,https://www.fool.com/investing/2023/10/08/2-healthcare-dividend-stocks-youd-regret-not-buy/,2023-10-08 12:15:00,"These stocks may not be for everyone, but income-seekers might find what they're looking for in them.",VTRS,0.498188,0.160555,Somewhat-Bullish
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October,https://www.globenewswire.com/news-release/2023/10/06/2756040/0/en/Ocuphire-Pharma-to-Present-at-Euretina-and-Retina-Society-Conferences-in-October.html,2023-10-06 12:00:00,Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy ...,VTRS,0.062761,0.02117,Neutral
Viatris makes progress on Ozempic patent challenge,https://www.marketwatch.com/story/viatris-makes-progress-on-ozempic-patent-challenge-990147ff,2023-10-04 21:05:00,Board agrees to review patent covering certain strengths of blockbuster diabetes drug ...,VTRS,0.782378,0.400994,Bullish
"Viatris  ( VTRS )  to Divest Some More Businesses, Shares Gain",https://www.zacks.com/stock/news/2159479/viatris-vtrs-to-divest-some-more-businesses-shares-gain,2023-10-03 16:28:00,Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.,VTRS,0.592455,0.412477,Bullish
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost - Novo Nordisk  ( NYSE:NVO ) ,https://www.benzinga.com/general/biotech/23/10/35066601/obesity-drug-wegovys-triumph-to-catapult-novo-holdings-in-golden-era-of-wealth-boost,2023-10-03 16:17:10,"Novo Holdings, the controlling shareholder of Novo Nordisk A/S NVO, is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.",VTRS,0.306963,-0.134265,Neutral
"Top Stories Tuesday, Oct 3: 'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals - Apple  ( NASDAQ:AAPL ) , ALX Oncology Holdings  ( NASDAQ:ALXO ) ",https://www.benzinga.com/news/23/10/35064552/airbnb-has-foundational-cracks-disney-follows-netflix-on-subscription-sharing-crackdown-microsofts-n,2023-10-03 14:11:20,"In a significant development, Microsoft Corp's MSFT CEO, Satya Nadella, has voiced concerns over the competitive landscape of content acquisition essential for training artificial intelligence ( AI ) .",VTRS,0.076236,0.067102,Neutral
"US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic",https://www.reuters.com/business/healthcare-pharmaceuticals/us-patent-office-wont-review-two-novo-nordisk-patents-wegovy-ozempic-2023-10-02/,2023-10-02 20:54:00,US Patent Office won't review two Novo Nordisk patents for ...,VTRS,0.468029,-0.125002,Neutral
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion,https://www.investors.com/news/technology/viatris-stock-bounds-higher-as-divestitures-reach-nearly-7-billion/,2023-10-02 14:55:00,"Viatris ( VTRS ) stock popped Monday after the generic drugs behemoth announced it would divest most of its over-the-counter and women's health businesses. Cooper Consumer Health, a leading European over-the-counter drugmaker and distributor, offered $2.17 billion to buy Viatris' ...",VTRS,0.900952,0.162789,Somewhat-Bullish
"Viatris to sell India women health care, API businesses for $1.2 billion",https://www.business-standard.com/health/viatris-sells-api-and-women-s-healthcare-business-in-india-for-1-2-bn-123100200845_1.html,2023-10-02 13:35:00,"US-based drugmaker Viatris, previously known as Mylan, is selling its active pharmaceutical ingredients ( API ) and women's health care businesses in India for a combined consideration of $1.2 billion ( nearly Rs 10,000 crore ) as part of a $3.6 billion global divestiture drive to pare debt.",VTRS,0.498587,0.196946,Somewhat-Bullish
"Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/markets/equities/23/10/35023947/viatris-phase-1-asset-divestiture-story-plans-to-sell-certain-otc-products-womens-healthcare-bus,2023-10-02 11:50:17,"Viatris Inc VTRS disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by the end of this year. The company expects to garner gross proceeds of about $6.94 billion from all asset sales sold under the agreement, representing multiple over 12x on 2022 ...",VTRS,0.526707,0.176333,Somewhat-Bullish
IQuest Enterprises to acquire active pharma ingredient business of Viatris,https://www.business-standard.com/companies/news/iquest-enterprises-to-acquire-active-pharma-ingredient-business-of-viatris-123100200569_1.html,2023-10-02 11:00:32,Multi-sector investment firm IQuest Enterprises will acquire the active pharmaceutical ingredients ( API ) business of Viatris in India for an undisclosed amount.,VTRS,0.651499,0.413212,Bullish
Viatris sells API & women's healthcare business in India for $1.2 billion,https://www.moneycontrol.com/news/business/companies/viatris-sells-api-womens-healthcare-business-in-india-for-1-2-billion-11464061.html,2023-10-02 10:27:54,Viatris has also sold its OTC ( over- the- counter ) business in Europe and commercialisation rights in a few non-core markets as part of a global divestiture drive to pare debt.,VTRS,0.434142,0.045615,Neutral
Drugmaker Viatris to divest some of its businesses,https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-viatris-divest-some-its-businesses-2023-10-01/,2023-10-01 21:18:00,"Oct 1 ( Reuters ) - Drugmaker Viatris ( VTRS.O ) said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Active Pharmaceutical Ingredients ( API ) business. It received an offer for the divestiture of its Over-the-Counter ( ...",VTRS,0.608634,0.352189,Bullish
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA,https://www.prnewswire.com/news-releases/viatris-announces-agreements-on-remaining-planned-divestitures-upon-closing-would-achieve-its-original-total-target-of-a-multiple-above-12x-on-2022-estimated-adjusted-ebitda-301943864.html,2023-10-01 21:00:00,Viatris Announces Agreements on Remaining Planned Divestitures. Upon Closing Would Achieve its Original Total ... PR ...,VTRS,0.506917,0.260685,Somewhat-Bullish
Could Viatris Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/09/30/could-viatris-stock-help-you-become-a-millionaire/,2023-09-30 11:58:00,Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment?,VTRS,0.637818,0.440606,Bullish
"Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report  ( UPDATED )  - Viatris  ( NASDAQ:VTRS ) , Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",https://www.benzinga.com/general/biotech/23/09/34900677/despite-efforts-vulnerable-patients-still-face-barriers-to-essential-medicines-says-new-1,2023-09-28 23:44:00,"Editor's note: This article has been updated with more details from the Access to Medicine Foundation's study. Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from ...",VTRS,0.235823,0.0,Neutral
Viatris  ( VTRS )  Gets FDA Nod for Pupil Dilation Reversal Agent,https://www.zacks.com/stock/news/2157157/viatris-vtrs-gets-fda-nod-for-pupil-dilation-reversal-agent,2023-09-28 14:48:00,Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.,VTRS,0.70166,0.234787,Somewhat-Bullish
"Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) , Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/news/23/09/34947896/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields,2023-09-27 13:03:32,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",VTRS,0.103778,0.0,Neutral
"Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™  ( Phentolamine Ophthalmic Solution )  0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists  ( e.g., Phenylephrine )  or Parasympatholytic  ( e.g., Tropicamide )  Agents - Viatris  ( NASDAQ:VTRS ) , Ocuphire Pharma  ( NASDAQ:OCUP ) ",https://www.benzinga.com/pressreleases/23/09/g34945083/ocuphire-pharma-and-viatris-announce-fda-approval-of-ryzumvi-phentolamine-ophthalmic-solution-0-75,2023-09-27 12:00:12,"FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders and Viatris ...",VTRS,0.305495,0.237451,Somewhat-Bullish
"Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™  ( Phentolamine Ophthalmic Solution )  0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists  ( e.g., Phenylephrine )  or Parasympatholytic  ( e.g., Tropicamide )  Agents",https://www.globenewswire.com/news-release/2023/09/27/2750331/0/en/Ocuphire-Pharma-and-Viatris-Announce-FDA-Approval-of-RYZUMVI-Phentolamine-Ophthalmic-Solution-0-75-Eye-Drops-for-the-Treatment-of-Pharmacologically-Induced-Mydriasis-Produced-by-Ad.html,2023-09-27 12:00:00,RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of ...,VTRS,0.311449,0.249783,Somewhat-Bullish
"Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report - Viatris  ( NASDAQ:VTRS ) , Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",https://www.benzinga.com/general/biotech/23/09/34900677/despite-efforts-vulnerable-patients-still-face-barriers-to-essential-medicines-says-new-report,2023-09-26 14:52:49,"Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to Medicine Foundation.",VTRS,0.268294,0.0,Neutral
The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... - PR Newswire,https://www.prnewswire.com/news-releases/the-thyroid-gland-disorder-treatment-market-to-grow-by-usd-868-87-million-from-2022-to-2027--abbott-laboratories-abbvie-inc-alvogen-iceland-ehf-and-more-among-key-companies--technavio-301936306.html,2023-09-25 02:15:00,The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... PR ...,VTRS,0.077845,0.027652,Neutral
"Safety Sectors For 2024: Yields Up To 6% In Healthcare, Staples",https://www.forbes.com/sites/brettowens/2023/09/24/safety-sectors-for-2024-yields-up-to-6-in-healthcare-staples/,2023-09-24 13:51:00,Worried that the Federal Reserve is driving our economy off a cliff? I've got two words for you: Drugs 'n diapers.,VTRS,0.206308,-0.085379,Neutral
"'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase - Alphabet  ( NASDAQ:GOOG ) , Alphabet  ( NASDAQ:GOOGL ) , Meta Platforms  ( NASDAQ:META ) , NVIDIA  ( NASDAQ:NVDA ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34825151/stocks-in-monopolistic-bull-market-wall-street-analyst-contemplates-a-bright-future,2023-09-22 14:46:19,"This year's bull market in stocks is a reflection of a bull market in monopolies and oligopolies, according to Bank of America's Chief Investment Strategist Michael Hartnett. While the S&P 500 boasts a commendable 14% year-to-date ( YTD ) increase, a closer look reveals the real action lies ...",VTRS,0.188193,-0.057826,Neutral
US FDA declines to approve ARS' emergency nasal spray for allergic reactions,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-ars-emergency-nasal-spray-allergic-reactions-2023-09-20/,2023-09-20 03:03:07,"Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Sept 19 ( Reuters ) - The U.S.",VTRS,0.113597,-0.071721,Neutral
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,2023-09-18 09:15:00,"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...",VTRS,0.043108,0.0,Neutral
"Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks",https://www.fool.com/investing/2023/09/14/want-to-collect-500-in-dividends-every-month-inves/,2023-09-14 13:18:00,These stocks offer some mouth-watering payouts.,VTRS,0.312158,0.213513,Somewhat-Bullish
Viatris Named to TIME's World's Best Companies 2023 List,https://www.prnewswire.com/news-releases/viatris-named-to-times-worlds-best-companies-2023-list-301925293.html,2023-09-12 18:45:00,"PITTSBURGH, Sept. 12, 2023 /PRNewswire/ -- ( NASDAQ: VTRS ) , a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list.",VTRS,0.497869,0.522146,Bullish
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/23/09/g34441899/ocuphire-pharma-to-participate-in-three-upcoming-investment-bank-conferences,2023-09-11 13:41:55,"FARMINGTON HILLS, Mich., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that ...",VTRS,0.053992,-0.066955,Neutral
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences,https://www.globenewswire.com/news-release/2023/09/11/2740925/0/en/Ocuphire-Pharma-to-Participate-in-Three-Upcoming-Investment-Bank-Conferences.html,2023-09-11 13:41:00,"FARMINGTON HILLS, Mich., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today ...",VTRS,0.054983,-0.058987,Neutral
Is Invesco S&P 500 Equal Weight Health Care ETF  ( RSPH )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2147014/is-invesco-sp-500-equal-weight-health-care-etf-rsph-a-strong-etf-right-now,2023-09-11 10:20:07,Smart Beta ETF report for ...,VTRS,0.12013,0.056456,Neutral
Female Sexual Dysfunction Treatment Market to grow by USD 7.76 billion from 2022-2027; North America to account ... - PR Newswire,https://www.prnewswire.com/news-releases/female-sexual-dysfunction-treatment-market-to-grow-by-usd-7-76-billion-from-2022-2027-north-america-to-account-for-61-of-market-growth---technavio-301922154.html,2023-09-11 07:35:00,Female Sexual Dysfunction Treatment Market to grow by USD 7.76 billion from 2022-2027. North America to account ... PR ...,VTRS,0.049019,0.043476,Neutral
3 Pharmaceutical Stocks That Are Too Cheap to Ignore,https://www.fool.com/investing/2023/09/09/pharmaceutical-stocks-that-are-too-cheap-to-ignore/,2023-09-09 11:20:00,"Viatris, GSK, and Organon are all trading at less than 7 times earnings.",VTRS,0.335628,0.313046,Somewhat-Bullish
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities,https://www.prnewswire.com/news-releases/oral-antiviral-market-report-2023-demand-for-novel-therapeutics-boosts-opportunities-301921979.html,2023-09-09 01:15:00,"DUBLIN, Sept. 8, 2023 /PRNewswire/ -- The ""Oral Antiviral Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031"" report has been added to ResearchAndMarkets.com's offering.",VTRS,0.085022,0.079948,Neutral
"Buzzing Stocks: Lupin, Hero MotoCorp, TCS, Responsive Industries & others in news today",https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-lupin-hero-motocorp-tcs-responsive-industries-others-in-news-today-11323981.html,2023-09-07 01:47:22,"Stocks to watch: Check out the companies making headlines before the opening bell, on September 6, 2023.",VTRS,0.142144,0.118087,Neutral
Theravance Bio  ( TBPH )  Down 2.3% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2145560/theravance-bio-tbph-down-23-since-last-earnings-report-can-it-rebound,2023-09-06 15:30:26,Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.065866,0.073095,Neutral
Why Is Viatris  ( VTRS )  Down 4.8% Since Last Earnings Report?,https://www.zacks.com/stock/news/2145557/why-is-viatris-vtrs-down-48-since-last-earnings-report,2023-09-06 15:30:26,Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.46066,0.129571,Neutral
Biocon Biologics completes integration of Viatris biosimilars business,https://www.business-standard.com/india-news/biocon-biologics-completes-integration-of-viatris-biosimilars-business-123090600805_1.html,2023-09-06 12:52:13,"Biocon on Wednesday said its arm Biocon Biologics has completed the integration of the acquired biosimilars business from Viatris in North America with effect from September 1, 2023.",VTRS,0.521465,0.127084,Neutral
"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule",https://www.prnewswire.com/news-releases/biocon-biologics-continues-to-expand-global-footprint-completes-integration-of-viatris-biosimilars-business-in-north-america-ahead-of-schedule-301916419.html,2023-09-06 11:00:00,"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North ... PR ...",VTRS,0.200688,0.243658,Somewhat-Bullish
"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule",https://www.prnewswire.com/in/news-releases/biocon-biologics-continues-to-expand-global-footprint-completes-integration-of-viatris-biosimilars-business-in-north-america-ahead-of-schedule-301916448.html,2023-09-06 11:00:00,"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North ... PR ...",VTRS,0.200688,0.243658,Somewhat-Bullish
"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule",https://www.newswire.ca/news-releases/biocon-biologics-continues-to-expand-global-footprint-completes-integration-of-viatris-biosimilars-business-in-north-america-ahead-of-schedule-859021205.html,2023-09-06 11:00:00,"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North ... Canada ...",VTRS,0.18602,0.230667,Somewhat-Bullish
Viatris  ( VTRS )  Gets Tentative Approval for HIV Regimen for Kids,https://www.zacks.com/stock/news/2144908/viatris-vtrs-gets-tentative-approval-for-hiv-regimen-for-kids,2023-09-05 14:36:00,"Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.",VTRS,0.644706,0.318857,Somewhat-Bullish
Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and Collaboration,https://www.prnewswire.com/news-releases/addressing-the-fragile-2023-global-osteogenesis-imperfecta-treatment-markets-growth-driven-by-research-and-collaboration-301916828.html,2023-09-04 15:45:00,Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and ... PR ...,VTRS,0.074001,0.048716,Neutral
Binge-eating Disorder Treatment Market size is set to grow by USD 578.04 million from 2022 to 2027 | The increasing ... - PR Newswire,https://www.prnewswire.com/news-releases/binge-eating-disorder-treatment-market-size-is-set-to-grow-by-usd-578-04-million-from-2022-to-2027--the-increasing-prevalence-of-binge-eating-disorder-drives-the-market---technavio-301916031.html,2023-09-04 15:15:00,Binge-eating Disorder Treatment Market size is set to grow by USD 578.04 million from 2022 to 2027 | The increasing ... PR ...,VTRS,0.046095,0.057979,Neutral
Biocon acquires Eywa Pharma's US-based manufacturing facility for $7.7 mn,https://www.business-standard.com/companies/news/biocon-acquires-eywa-pharma-s-us-based-manufacturing-facility-for-7-7-mn-123090200623_1.html,2023-09-02 12:03:10,"Biopharma company Biocon's wholly owned subsidiary, Biocon Generics, has acquired the oral solid dosage manufacturing facility of US-based Eywa Pharma Inc located in Cranbury, New Jersey for $7.7 million ( Rs 63 crore ) . The acquisition is effective September 1.",VTRS,0.205807,0.200412,Somewhat-Bullish
Could CVS Make a Copy of Ozempic?,https://www.fool.com/investing/2023/09/02/could-cvs-make-a-copy-of-ozempic/,2023-09-02 11:35:00,"Given its new biosimilars unit, copying Ozempic is more likely than it sounds.",VTRS,0.096283,0.045099,Neutral
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know,https://www.fool.com/investing/2023/09/01/cvs-health-just-created-a-new-problem-for-viatris/,2023-09-01 12:30:00,CVS just fired a shot across Viatris' bow.,VTRS,0.708055,0.167307,Somewhat-Bullish
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse,https://www.reuters.com/business/healthcare-pharmaceuticals/generic-drugmakers-start-shipping-copies-takedas-adhd-drug-vyvanse-2023-08-31/,2023-08-31 19:49:00,Generic drugmakers start shipping copies of Takeda's ADHD drug ...,VTRS,0.150592,0.002639,Neutral
Viatris Stock: Bear vs. Bull,https://www.fool.com/investing/2023/08/31/viatris-stock-bear-vs-bull/,2023-08-31 12:45:00,This is a case where both sides have compelling arguments.,VTRS,0.496741,0.28126,Somewhat-Bullish
On track to integrate major part of Viatris' acquired biosimilars business this fiscal: Kiran Mazumdar-Shaw,https://www.financialexpress.com/business/industry-on-track-to-integrate-major-part-of-viatris-acquired-biosimilars-business-this-fiscal-kiran-mazumdar-shaw-3227965/,2023-08-30 15:08:05,"Biocon Biologics is on track to integrate a major part of the acquired biosimilars business of long-term partner Viatris in the current fiscal, the company's Executive Chairperson Kiran Mazumdar-Shaw has said.",VTRS,0.431065,0.092807,Neutral
Viatris  ( VTRS ) 's Technical Outlook is Bright After Key Golden Cross,https://www.zacks.com/stock/news/2142438/viatris-vtrss-technical-outlook-is-bright-after-key-golden-cross,2023-08-30 13:55:02,"When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?",VTRS,0.497391,0.497486,Bullish
4 Of The Cheapest Value Stocks Paying 3+% Dividends,https://www.forbes.com/sites/johnnavin/2023/08/29/4-of-the-cheapest-value-stocks-paying-3-dividends/,2023-08-29 16:42:28,These 4 stocks are not widely mentioned in the financial media and it's unlikely you'll find them listed as components of any Cathie Woods portfolios.,VTRS,0.165031,0.080704,Neutral
Fertility Supplement Global Market to Exhibit Growth at a CAGR of ~8% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/fertility-supplement-global-market-to-exhibit-growth-at-a-cagr-of-8-by-2028--delveinsight-301911682.html,2023-08-28 21:32:00,"The demand for fertility supplements is being driven primarily by key factors such as an increase in the number of cases of infertility, an increase in risk factors associated with causing infertility, growing reproductive health awareness, and an increase in product launches, all of which are ...",VTRS,0.028558,-0.002762,Neutral
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders,https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-new-ampreloxetine-data-at-the-2023-international-congress-of-parkinsons-disease-and-movement-disorders-301911054.html,2023-08-28 10:23:00,Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease ... PR ...,VTRS,0.023057,0.069548,Neutral
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders,https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-new-ampreloxetine-data-at-the-2023-international-congress-of-parkinsons-disease-and-movement-disorders-301911053.html,2023-08-28 10:05:00,Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease ... PR ...,VTRS,0.023057,0.069548,Neutral
Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... - PR Newswire,https://www.prnewswire.com/news-releases/multiple-sclerosis-market-in-the-us-to-grow-by-usd-3-95-billion-from-2021-to-2026--rising-prevalence-of-multiple-sclerosis-will-drive-growth---technavio-301909378.html,2023-08-26 00:30:00,Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... PR ...,VTRS,0.059785,0.185027,Somewhat-Bullish
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris,https://www.fool.com/investing/2023/08/24/better-high-yield-dividend-stock-takeda-pharmaceut/,2023-08-24 21:00:00,One of these high-yield pharma stocks stands out as a better buy right now.,VTRS,0.819293,0.225466,Somewhat-Bullish
Contraceptives Global Market Exhibit Growth at a CAGR of ~5% by 2027 | DelveInsight,https://www.prnewswire.com/news-releases/contraceptives-global-market-exhibit-growth-at-a-cagr-of-5-by-2027--delveinsight-301907623.html,2023-08-23 21:01:00,"The contraceptives market is experiencing positive growth as a result of increased awareness about sexually transmitted diseases, an increase in government initiatives for population control, an increase in unintended pregnancies, and technological innovations leading to effective contraception, ...",VTRS,0.06697,0.006022,Neutral
Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33967522/regenerons-crucial-eylea-hd-approval-a-shield-against-potential-biosimilar-competit,2023-08-21 19:04:31,"Friday, the FDA approved Regeneron Pharmaceuticals Inc's REGN approved Eylea HD ( aflibercept ) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy ( DR ) .",VTRS,0.104228,0.260211,Somewhat-Bullish
HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... - PR Newswire,https://www.prnewswire.com/news-releases/hiv-drugs-market-size-to-grow-by-usd-10-47-biilion-from-2022-to-2027--expanding-access-to-hiv-treatment-is-a-major-trend--technavio-301905076.html,2023-08-21 11:30:00,HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... PR ...,VTRS,0.064973,0.102266,Neutral
Here's Why You Should Add Dr. Reddy's  ( RDY )  to Your Portfolio,https://www.zacks.com/stock/news/2138212/heres-why-you-should-add-dr-reddys-rdy-to-your-portfolio,2023-08-18 16:22:00,Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.,VTRS,0.038843,-0.099779,Neutral
Where Will Viatris Be in 5 Years?,https://www.fool.com/investing/2023/08/18/where-will-viatris-be-in-5-years/,2023-08-18 11:45:00,Can this become a good growth business to invest in?,VTRS,0.749619,0.239691,Somewhat-Bullish
Stocks To Watch: Viatris Sees Relative Strength Rating Rise To 84,https://www.investors.com/ibd-data-stories/stocks-to-watch-viatris-sees-relative-strength-rating-rise-to-84/,2023-08-18 07:00:00,"On Friday, Viatris ( VTRS ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 84, up from 79 the day before. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price ...",VTRS,0.601928,0.439293,Bullish
"Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?",https://www.fool.com/investing/2023/08/16/viatris-make-generic-ozempic-stock-a-buy/,2023-08-16 15:06:18,There are a few complicating factors that mean the generic form of the drug might not be a slam dunk.,VTRS,0.695767,0.140823,Neutral
"Top Stocks to Watch today, August 14: Adani Ports, Nykaa, Raymond, PSU Banks, Biocon",https://www.business-standard.com/markets/news/stocks-to-watch-today-aug-14-adani-ports-nykaa-raymond-psu-banks-biocon-123081400077_1.html,2023-08-14 02:31:08,"Stocks to Watch on Aug 14: Adani Ports, Nykaa, Raymond, PSU Banks, Biocon Business Standard ...",VTRS,0.039614,0.048132,Neutral
Biocon may list biosimilars business by 2025 first half - CEO,https://www.moneycontrol.com/news/business/biocon-may-list-biosimilars-business-by-2025-first-half-ceo-11163871.html,2023-08-11 15:30:22,"Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.",VTRS,0.149656,-0.069505,Neutral
Biocon may list biosimilars business by 2025 first half - CEO,https://www.reuters.com/markets/deals/biocon-may-list-biosimilars-business-by-2025-first-half-ceo-2023-08-11/,2023-08-11 14:54:00,"An employee of Biocon Ltd works inside the company's research and development centre in Bengaluru, India, October 16, 2015. REUTERS/Abhishek N. Chinnappa/File Photo",VTRS,0.131643,-0.064788,Neutral
2 Beaten-Down Dividend Stocks to Buy,https://www.fool.com/investing/2023/08/11/2-beaten-down-dividend-stocks-to-buy/,2023-08-11 14:00:00,These two stocks look like bargains right now for income investors.,VTRS,0.63878,0.266428,Somewhat-Bullish
"If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today",https://www.fool.com/investing/2023/08/11/if-youd-invested-25000-in-viatris-in-2020-this-is/,2023-08-11 12:25:00,Would you have been better off investing in the S&P 500?,VTRS,0.752738,0.106844,Neutral
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/11/2723507/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Second-Quarter-2023-and-Provides-Corporate-Update.html,2023-08-11 12:00:00,End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy ( DR ...,VTRS,0.019683,-0.052405,Neutral
Biocon shares fall 3% after Q1 net profit slumps 30%,https://www.moneycontrol.com/news/business/stocks/biocon-shares-fall-3-after-q1-net-profit-slumps-30-11152811.html,2023-08-11 04:06:56,"Despite a drop in net profit, revenue for Biocon continued to surge on the back of two-fold increase in the biosimilars business, accompanied by a double-digit growth in the generics and research services segments.",VTRS,0.109956,0.236653,Somewhat-Bullish
India's Biocon Q1 profit falls on higher R&D spending,https://www.reuters.com/business/healthcare-pharmaceuticals/indias-biocon-q1-profit-falls-higher-rd-spending-2023-08-10/,2023-08-10 17:02:00,"HYDERABAD, Aug 10 ( Reuters ) - India's Biocon ( BION.NS ) on Thursday posted a 29.8% fall in June-quarter profit, hurt by increased spending in research and development ( R&D ) .",VTRS,0.147818,0.369169,Bullish
Viatris Trying To Close In On Key Technical Measure,https://www.investors.com/ibd-data-stories/viatris-trying-to-close-in-on-key-technical-measure/,2023-08-10 07:00:00,"In a welcome move, Viatris ( VTRS ) saw its Relative Strength Rating improve from 65 to 71 on Thursday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating tracks share price performance with a 1 ( worst ) to 99 ( best ...",VTRS,0.702434,0.432524,Bullish
Is Viatris Stock Good for Dividend Income?,https://www.fool.com/investing/2023/08/09/is-viatris-stock-good-for-dividend-income/,2023-08-09 13:37:00,"If you keep your expectations in check, it could be a great pick.",VTRS,0.567144,0.335843,Somewhat-Bullish
"Theravance's  ( TBPH )  Q2 Earnings Beat Estimates, Revenues Miss",https://www.zacks.com/stock/news/2133720/theravances-tbph-q2-earnings-beat-estimates-revenues-miss,2023-08-08 13:54:00,Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.,VTRS,0.403172,0.310276,Somewhat-Bullish
"Company News for Aug 8, 2023",https://www.zacks.com/stock/news/2133635/company-news-for-aug-8-2023,2023-08-08 13:42:00,Companies in The News Are: ...,VTRS,0.535653,0.556401,Bullish
"Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2023-financial-results-and-provides-business-update-301894966.html,2023-08-07 20:05:00,"DUBLIN, Aug. 7, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ( ""Theravance Biopharma"" or the ""Company"" ) ( NASDAQ: TBPH ) today announced financial and operational results for the second quarter of 2023.",VTRS,0.158693,0.098175,Neutral
"Viatris  ( VTRS )  Q2 Earnings Beat, Generics Business Grows",https://www.zacks.com/stock/news/2133251/viatris-vtrs-q2-earnings-beat-generics-business-grows,2023-08-07 16:08:00,Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.,VTRS,0.651499,0.114021,Neutral
"Stocks making the biggest moves midday: Tesla, Berkshire Hathaway, PayPal, Cinemark and more",https://www.cnbc.com/2023/08/07/stocks-making-the-biggest-moves-midday-tsla-brka-pypl-cnk.html,2023-08-07 16:07:45,These are the stocks posting the largest moves in midday trading.,VTRS,0.170275,0.067255,Neutral
"Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/general/biotech/23/08/33600035/viatris-q2-earnings-beat-estimates-multiple-sclerosis-therapy-accepted-for-fda-review,2023-08-07 15:35:56,"Viatris Inc VTRS reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the consensus of $3.89 billion. Brands performed in line with expectations, reflecting strong year-over-year performance in key brands, including Yupelri and sales from ...",VTRS,0.642555,0.373817,Bullish
"Viatris beats second-quarter revenue estimates, says divestiture plans on track",https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-beats-second-quarter-revenue-estimates-says-divestiture-plans-track-2023-08-07/,2023-08-07 12:29:00,"Aug 7 ( Reuters ) - Viatris Inc ( VTRS.O ) beat Wall Street estimates for second-quarter revenue on Monday, on the strength of its branded drug portfolio, sending its shares up 2% in premarket trading.",VTRS,0.509589,0.104434,Neutral
"Stocks making the biggest moves premarket: Sovos Brands, BioNTech, Tyson Foods and more",https://www.cnbc.com/2023/08/07/stocks-making-the-biggest-moves-premarket-sovo-bntx-tsn-.html,2023-08-07 12:17:55,Shares of Rao's parent Sovos Brands' popped 25% in premarket trading on news that Campbell Soup will acquire the pasta sauce maker for $2.33 billion.,VTRS,0.151064,0.234943,Somewhat-Bullish
Viatris  ( VTRS )  Q2 Earnings and Revenues Beat Estimates,https://www.zacks.com/stock/news/2133030/viatris-vtrs-q2-earnings-and-revenues-beat-estimates,2023-08-07 12:15:09,"Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.404563,0.1467,Neutral
Viatris Inc. Q2 Profit Drops,https://markets.businessinsider.com/news/stocks/viatris-inc-q2-profit-drops-1032523430,2023-08-07 12:11:30,"( RTTNews ) - Viatris Inc. ( VTRS ) announced earnings for second quarter that decreased from last year The company's earnings totaled $264.0 million, or $0.22 per share. This compares with $313.9 million, or $0.26 per share, in last year's second quarter.",VTRS,0.751437,0.0,Neutral
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1],https://www.prnewswire.com/news-releases/viatris-reports-strong-financial-and-operational-results-for-second-quarter-2023-and-reaffirms-full-year-2023-guidance-ranges1-301894251.html,2023-08-07 10:59:00,Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 ... PR ...,VTRS,0.307251,0.199746,Somewhat-Bullish
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis,https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-ga-depot-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-301894145.html,2023-08-07 10:54:00,Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of ... PR ...,VTRS,0.437261,0.3733,Bullish
"Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years",https://www.fool.com/investing/2023/08/04/want-1500-in-annual-passive-income-invest-this-muc/,2023-08-04 12:20:00,"If you're patient and consistent, it won't be too hard to build up a revenue stream.",VTRS,0.483686,0.426169,Bullish
The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire,https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html,2023-08-04 09:30:00,The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...,VTRS,0.045569,0.139204,Neutral
Viatris  ( VTRS )  to Report Q2 Earnings: What's in the Offing?,https://www.zacks.com/stock/news/2129982/viatris-vtrs-to-report-q2-earnings-whats-in-the-offing,2023-07-31 15:45:00,"Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.",VTRS,0.652576,0.299192,Somewhat-Bullish
"Topical Corticosteroids Market size to grow by USD 1,089.66 million from 2022 to 2027|Advancements in drug delivery ... - PR Newswire",https://www.prnewswire.com/news-releases/topical-corticosteroids-market-size-to-grow-by-usd-1-089-66-million-from-2022-to-2027advancements-in-drug-delivery-systems-to-boost-market-growth---technavio-301888372.html,2023-07-31 14:15:00,"Topical Corticosteroids Market size to grow by USD 1,089.66 million from 2022 to 2027|Advancements in drug delivery ... PR ...",VTRS,0.034984,0.103998,Neutral
"Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First ... - PR Newswire",https://www.prnewswire.com/news-releases/viatris-announces-launch-of-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-the-first-fda-approved-generic-version-of-symbicort-for-people-with-asthma-and-chronic-obstructive-pulmonary-disease-in-partn-301888925.html,2023-07-31 10:59:00,"Viatris Announces Launch of Breyna™ ( budesonide and formoterol fumarate dihydrate ) Inhalation Aerosol, the First ... PR ...",VTRS,0.252201,0.201388,Somewhat-Bullish
Dr Reddy's Labs ADR Reaches 80-Plus Relative Strength Rating Benchmark,https://www.investors.com/ibd-data-stories/dr-reddys-labs-adr-reaches-80-plus-relative-strength-rating-benchmark/,2023-07-25 07:00:00,"Dr Reddy's Labs ADR ( RDY ) had its Relative Strength ( RS ) Rating upgraded from 79 to 82 Tuesday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",VTRS,0.329551,0.0,Neutral
"Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept",https://www.prnewswire.com/news-releases/biocon-biologics-announces-positive-chmp-opinion-for-yesafili-biosimilar-aflibercept-301883594.html,2023-07-24 10:30:00,"BRIDGEWATER, N.J. and BENGALURU, India, July 24, 2023 /PRNewswire/ -- Biocon Biologics Ltd ( BBL ) , a subsidiary of Biocon Ltd ( BSE code: 532523, NSE: BIOCON ) , today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive ...",VTRS,0.044634,0.143918,Neutral
"Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept",https://www.newswire.ca/news-releases/biocon-biologics-announces-positive-chmp-opinion-for-yesafili-r-biosimilar-aflibercept-820062816.html,2023-07-24 10:30:00,"BRIDGEWATER, N.J. and BENGALURU, India, July 24, 2023 /CNW/ -- Biocon Biologics Ltd ( BBL ) , a subsidiary of Biocon Ltd ( BSE code: 532523, NSE: BIOCON ) , today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive opinion ...",VTRS,0.041538,0.142897,Neutral
Viatris Stock: Bull vs. Bear,https://www.fool.com/investing/2023/07/22/viatris-stock-bull-vs-bear/,2023-07-22 10:00:00,Viatris shares have declined in the double digits over the past few years.,VTRS,0.768826,0.330064,Somewhat-Bullish
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock,https://www.fool.com/investing/2023/07/20/1-reason-i-wouldnt-buy-this-high-yielding-dividend/,2023-07-20 13:20:00,"Unless you're only in it for the dividend, you might be disappointed with this stock.",VTRS,0.6584,0.056124,Neutral
Undue influence? Anonymous donations to World Health Organization's new foundation raise concerns,https://apnews.com/article/who-foundation-global-health-funding-e1a35f3ef63356100f07549f317512ca,2023-07-20 12:12:00,"Nearly 40% of the money raised by the WHO Foundation in its first two years came from anonymous sources, worrying some that donors may be trying to influence the World Health Organization and its role in shaping global health policy with their gifts.",VTRS,0.038162,0.041124,Neutral
Better Pharma Buy: Viatris vs. Pfizer,https://www.fool.com/investing/2023/07/19/better-pharma-buy-viatris-vs-pfizer/,2023-07-19 18:00:00,Both stocks look cheap today.,VTRS,0.635488,0.387214,Bullish
Better High-Yield Dividend Stock: Altria or Viatris?,https://www.fool.com/investing/2023/07/15/better-high-yield-dividend-stock-altria-or-viatris/,2023-07-15 21:00:00,Which of these top income stocks is the better buy right now?,VTRS,0.778186,0.148357,Neutral
"3 Reasons to Buy Viatris Stock, and 1 Reason to Sell",https://www.fool.com/investing/2023/07/14/3-reasons-to-buy-viatris-and-1-reason-to-sell/,2023-07-14 11:45:00,This drugmaker could be a great stock to own over the coming years.,VTRS,0.656549,0.23424,Somewhat-Bullish
"VTRS, VIRT & CRL Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/07/g33216448/vtrs-virt-crl-class-action-reminders-bronstein-gewirtz-grossman-llc-a-top-firm-reminds-investors-o,2023-07-13 14:00:00,"NEW YORK, July 13, 2023 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.",VTRS,0.254307,0.072571,Neutral
3 Healthcare Stocks With Healthy Dividends,https://www.fool.com/investing/2023/07/13/3-healthcare-stocks-with-healthy-dividends/,2023-07-13 13:05:00,These pharmaceutical companies all combine relatively high dividends with safe payout ratios.,VTRS,0.176502,0.131493,Neutral
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys Before July 14th Deadline in Securities Fraud Class Action - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/07/g33191964/hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors-with-substantial-losses-t,2023-07-11 22:54:48,"SAN FRANCISCO, July 11, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.307329,Somewhat-Bullish
"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS",https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-viatris-inc-of-class-action-lawsuit-and-upcoming-deadline--vtrs-301874653.html,2023-07-11 20:46:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of ... PR ...",VTRS,0.77735,0.115338,Neutral
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit,https://www.prnewswire.com/news-releases/vtrs-investors-have-opportunity-to-lead-viatris-inc-securities-fraud-lawsuit-301874609.html,2023-07-11 20:17:00,"LOS ANGELES, July 11, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ( ""GPM"" ) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Viatris Inc. ( ""Viatris"" or the ""Company"" ) ( NASDAQ: VTRS ) .",VTRS,0.570165,0.218082,Somewhat-Bullish
"Viatris Inc: Please contact the Portnoy Law Firm to recover your losses; July 14, 2023 deadline - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/07/g33189782/viatris-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-july-14-2023-deadline,2023-07-11 18:17:03,Investors can contact the law firm at no cost to learn more about recovering their losses,VTRS,0.508593,0.090018,Neutral
VIATRIS INC.  ( NASDAQ: VTRS )  SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/07/g33177738/viatris-inc-nasdaq-vtrs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-of,2023-07-11 05:45:00,"NEW YORK, July 11, 2023 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Viatris, Inc. VTRS? Did you purchase your shares between March 1, 2021 and February 25, 2022, inclusive? Did you lose money in your investment in Viatris, Inc.?",VTRS,0.627549,0.178463,Somewhat-Bullish
"Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Ocuphire Pharma  ( NASDAQ:OCUP ) ",https://www.benzinga.com/pressreleases/23/07/g33174819/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4,2023-07-10 21:19:14,"FARMINGTON HILLS, Mich., July 10, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc.",VTRS,0.071784,-0.067633,Neutral
"Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ",https://www.globenewswire.com/news-release/2023/07/10/2702220/0/en/Ocuphire-Pharma-Inc-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2023-07-10 21:19:00,"FARMINGTON HILLS, Mich., July 10, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. ( Nasdaq: OCUP ) , today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire's 2021 Inducement Plan, as ...",VTRS,0.075161,-0.059855,Neutral
3 Beaten-Down Dividend Stocks That Look Like Bargains Right Now,https://www.fool.com/investing/2023/07/10/3-beaten-down-dividend-stocks-that-look-like-barga/,2023-07-10 09:12:00,These stocks have fallen so far over the past six months that they look like bargains that income-seeking investors don't want to pass up.,VTRS,0.281692,0.187927,Somewhat-Bullish
"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/07/g33158707/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-viatr,2023-07-09 20:15:30,"NEW YORK, July 09, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ( ""Viatris"" or the ""Company"" ) VTRS, and certain officers.",VTRS,0.771727,0.095212,Neutral
"VIATRIS DEADLINE ALERT: Securities Litigation Partner James  ( Josh )  Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options",https://www.prnewswire.com/news-releases/viatris-deadline-alert-securities-litigation-partner-james-josh-wilson-encourages-investors-who-suffered-losses-exceeding-100-000-in-viatris-to-contact-him-directly-to-discuss-their-options-301872334.html,2023-07-08 11:00:00,VIATRIS DEADLINE ALERT: Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered ... PR ...,VTRS,0.633079,0.211823,Somewhat-Bullish
"ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS",https://www.prnewswire.com/news-releases/rosen-national-trial-lawyers-encourages-viatris-inc-investors-to-secure-counsel-before-important-july-14-deadline-in-securities-class-action--vtrs-301872148.html,2023-07-07 18:45:00,"ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 ... PR ...",VTRS,0.612343,0.229265,Somewhat-Bullish
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Viatris  ( VTRS )  Investors to July 14th Deadline in Securities Fraud Class Action, Urges Investors with Substantial Losses to Contact Firm's Attorneys",https://markets.businessinsider.com/news/stocks/hagens-berman-national-trial-attorneys-alerts-viatris-vtrs-investors-to-july-14th-deadline-in-securities-fraud-class-action-urges-investors-with-substantial-losses-to-contact-firms-attorneys-1032432403,2023-07-07 13:40:00,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Viatris (VTRS) Investors to July 14th Deadline in Securities Fraud Class Action, Urges Investors with Substantial Losses to Contact Firm's Attorneys ...",VTRS,0.645887,0.335587,Somewhat-Bullish
Why Dividend Stocks Should Be a Key Part of Your Retirement Plan,https://www.fool.com/investing/2023/07/07/dividend-stocks-should-be-part-of-your-retirement/,2023-07-07 11:15:00,You can collect the dividend income while keeping your original investment intact.,VTRS,0.224383,0.121702,Neutral
"VTRS 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys Before July 14th Deadline in Securities Fraud Class Action - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/07/g33137247/vtrs-8-day-deadline-alert-hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors,2023-07-06 17:19:35,"SAN FRANCISCO, July 06, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.307329,Somewhat-Bullish
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/07/g33135220/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-07-06 15:15:00,"LOS ANGELES, July 06, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc.  ( VTRS )  - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/07/g33134984/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-agains,2023-07-06 15:08:00,"LOS ANGELES, July 06, 2023 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( ""GPM"" ) reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Viatris Inc. ( ""Viatris"" or the ...",VTRS,0.516883,0.124951,Neutral
"VTRS, VIRT & CRL Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/07/g33133446/vtrs-virt-crl-class-action-reminders-bronstein-gewirtz-grossman-llc-a-top-firm-reminds-investors-o,2023-07-06 14:00:00,"NEW YORK, July 06, 2023 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.",VTRS,0.254307,0.072571,Neutral
Biocon gains as arm takes over commercialization of biosimilars business,https://www.moneycontrol.com/news/business/markets/biocon-gains-as-arm-takes-over-commercialization-of-biosimilars-business-10912311.html,2023-07-06 04:20:59,Biocon Biologics had signed a deal to acquire Viatris Inc's biosimilars business for $3.33 billion in February ...,VTRS,0.642555,0.179346,Somewhat-Bullish
Biocon Biologics eyes third of FY24 revenue from emerging markets,https://www.business-standard.com/companies/news/emerging-mkts-to-contribute-one-third-of-biocon-biologics-revenues-in-fy24-123070600745_1.html,2023-07-06 02:36:00,"Biocon Biologics ( BBL ) , a subsidiary of Biocon Ltd, is expecting 33 per cent of its revenues from emerging markets in FY24, a day after the firm completed the integration of the acquired biosimilars business from Viatris in over 70 countries.",VTRS,0.885652,0.0,Neutral
Biocon Biologics expands its footprint in Emerging Markets; takes over commercialization of Biosimilars Business from Viatris | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/biocon-biologics-expands-its-footprint-in-emerging-markets-takes-over-commercialization-of-biosimilars-business-from-viatris/3157733/,2023-07-06 01:30:00,Biocon Biologics expands its footprint in Emerging Markets. takes over commercialization of Biosimilars Business from Viatris The Financial Express ...,VTRS,0.375251,0.290807,Somewhat-Bullish
"Buzzing Stocks: JSW Steel, DCB Bank, Ujjivan Small Finance, RPP Infra & others in news today",https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-jsw-steel-dcb-bank-ujjivan-small-finance-rpp-infra-others-in-news-today-10911111.html,2023-07-06 01:22:59,Stocks to Watch: Check out the companies making headlines before the opening bell today.,VTRS,0.053035,0.12565,Neutral
SHAREHOLDER CLASS ACTION REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc.  ( NASDAQ: VTRS )  - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/07/g33119088/shareholder-class-action-reminder-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file,2023-07-05 16:30:00,"Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at ( 212 ) 951-2030 or pallocco@bernlieb.com to discuss your rights.",VTRS,0.585052,0.161531,Somewhat-Bullish
"Biocon Biologics expands to over 70 countries, enters emerging markets",https://www.business-standard.com/companies/news/biocon-biologics-expands-to-over-70-countries-enters-emerging-markets-123070500706_1.html,2023-07-05 13:26:49,"Biocon Biologics ( BBL ) has now taken the commercialisation of biosimilars business from Viatris in over 70 countries, thereby expanding the footprint in emerging markets.",VTRS,0.856646,0.172741,Somewhat-Bullish
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?,https://www.fool.com/investing/2023/07/05/wall-street-viatris-stock-rise-25-could-grow-more/,2023-07-05 10:08:00,"There are a few trends moving in the right direction, and they could easily add up.",VTRS,0.340245,0.184423,Somewhat-Bullish
Aurobindo Pharma gains on positive Phase-3 results of breast cancer drug,https://www.moneycontrol.com/news/business/stocks/aurobindo-pharma-gains-on-positive-phase-3-results-of-breast-cancer-drug-10903651.html,2023-07-05 04:24:44,"This phase 3 study is a multi-centre, randomized, double-blinded study involving females with metastatic HER2- positive breast cancer, company said.",VTRS,0.273807,0.374946,Bullish
Biocon Biologics' biosimilar of Humira is now available in United States | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/biocon-biologics-biosimilar-of-humira-is-now-available-in-united-states/3154596/,2023-07-04 06:07:00,Biocon Biologics' biosimilar of Humira is now available in United States The Financial Express ...,VTRS,0.213988,0.122002,Neutral
"Biocon Biologics introduces Hulio, a Humira biosimilar for rheumatoid arthritis, in US",https://www.moneycontrol.com/news/business/biocon-biologics-introduces-hulio-a-humira-biosimilar-for-rheumatoid-arthritis-in-us-10899581.html,2023-07-04 04:33:20,"The drug has been made available to patients in the United States after five years of experience in Europe and two years in Canada, the release said.",VTRS,0.105604,0.0,Neutral
"Buzzing Stocks: IDFC First Bank, Vedanta, Anupam Rasayan, Bajaj Finance, others in news",https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-idfc-first-bank-vedanta-anupam-rasayan-bajaj-finance-others-in-news-10897521.html,2023-07-04 01:35:32,Stocks to Watch: Check out the companies making headlines before the opening bell today.,VTRS,0.137409,0.180381,Somewhat-Bullish
"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS",https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-viatris-inc-of-class-action-lawsuit-and-upcoming-deadline--vtrs-301869126.html,2023-07-03 19:40:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of ... PR ...",VTRS,0.77735,0.115338,Neutral
"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES",https://www.prnewswire.com/in/news-releases/after-five-years-of-successful-experience-internationally-biocon-biologics-hulio-biosimilar-to-humira-now-available-in-the-united-states-301869163.html,2023-07-03 17:16:00,"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO ... PR ...",VTRS,0.136113,0.077955,Neutral
"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES",https://www.prnewswire.com/news-releases/after-five-years-of-successful-experience-internationally-biocon-biologics-hulio-biosimilar-to-humira-now-available-in-the-united-states-301869134.html,2023-07-03 16:40:00,"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO ... PR ...",VTRS,0.118146,0.072826,Neutral
"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES",https://www.newswire.ca/news-releases/after-five-years-of-successful-experience-internationally-biocon-biologics-hulio-r-biosimilar-to-humira-r-now-available-in-the-united-states-860580293.html,2023-07-03 16:40:00,"AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO ... Canada ...",VTRS,0.108117,0.073687,Neutral
"VTRS 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys Before July 14th Deadline in Securities...",https://markets.businessinsider.com/news/stocks/vtrs-12day-deadline-alert-hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors-with-substantial-losses-to-contact-firms-attorneys-before-july-14th-deadline-in-securities-fraud-class-action-1032422197,2023-07-02 13:06:00,"VTRS 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Viatris (VTRS) Investors with Substantial Losses to Contact Firm's Attorneys Before July 14th Deadline in Securities...",VTRS,0.645887,0.335587,Somewhat-Bullish
"VIATRIS DEADLINE ALERT : Securities Litigation Partner James  ( Josh )  Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options",https://www.prnewswire.com/news-releases/viatris-deadline-alert--securities-litigation-partner-james-josh-wilson-encourages-investors-who-suffered-losses-exceeding-100-000-in-viatris-to-contact-him-directly-to-discuss-their-options-301867477.html,2023-07-01 11:00:00,VIATRIS DEADLINE ALERT : Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered ... PR ...,VTRS,0.633079,0.211823,Somewhat-Bullish
"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS",https://www.prnewswire.com/news-releases/rosen-a-leading-and-longstanding-firm-encourages-viatris-inc-investors-to-secure-counsel-before-important-july-14-deadline-in-securities-class-action--vtrs-301868098.html,2023-06-30 23:30:00,"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before ... PR ...",VTRS,0.612343,0.229265,Somewhat-Bullish
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc.  ( VTRS )  - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/06/g33080032/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-agains,2023-06-30 15:08:00,"LOS ANGELES, June 30, 2023 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( ""GPM"" ) reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Viatris Inc. ( ""Viatris"" or the ...",VTRS,0.516883,0.124951,Neutral
"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 14, 2023 -  ( NASDAQ: VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g33063319/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-viatris-inc-of-a-class-action-lawsui,2023-06-29 16:27:00,"NEW YORK, June 29, 2023 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.",VTRS,0.512933,0.159945,Somewhat-Bullish
"VTRS, VIRT & CRL Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g33059855/vtrs-virt-crl-class-action-reminders-bronstein-gewirtz-grossman-llc-a-top-firm-reminds-investors-o,2023-06-29 14:00:00,"NEW YORK, June 29, 2023 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.",VTRS,0.254307,0.072571,Neutral
"DEADLINE ALERT for BYND, DIS, STEM, VTRS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - Beyond Meat  ( NASDAQ:BYND ) , Walt Disney  ( NYSE:DIS ) ",https://www.benzinga.com/pressreleases/23/06/g33053099/deadline-alert-for-bynd-dis-stem-vtrs-law-offices-of-howard-g-smith-reminds-investors-of-class-act,2023-06-29 01:27:00,"BENSALEM, Pa., June 28, 2023 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.168785,0.063515,Neutral
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g33044972/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-06-28 15:15:00,"LOS ANGELES, June 28, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
Viatris  ( VTRS )  Flat As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2113910/viatris-vtrs-flat-as-market-gains-what-you-should-know,2023-06-27 22:15:22,"Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.",VTRS,0.674691,0.203459,Somewhat-Bullish
"ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g33016064/rosen-a-longstanding-and-trusted-firm-encourages-viatris-inc-investors-with-losses-to-secure-couns,2023-06-26 22:30:00,"NEW YORK, June 26, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead ...",VTRS,0.544495,0.095628,Neutral
"VTRS CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g33011947/vtrs-class-action-hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors-with-su,2023-06-26 18:24:07,"SAN FRANCISCO, June 26, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.310824,Somewhat-Bullish
"Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts - Organon  ( NYSE:OGN ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/06/33005212/check-out-3-health-care-stocks-with-over-4-dividend-yields-from-wall-streets-most-accurate-analysts,2023-06-26 13:08:44,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",VTRS,0.107978,0.337562,Somewhat-Bullish
"ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",https://markets.businessinsider.com/news/stocks/rosen-global-investor-counsel-encourages-viatris-inc.-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032408403,2023-06-26 02:24:23,"ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before ... - Markets Insider ...",VTRS,0.606182,0.129646,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g33000192/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-viatr,2023-06-26 02:21:55,"NEW YORK, June 25, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ( ""Viatris"" or the ""Company"" ) VTRS, and certain officers.",VTRS,0.771727,0.095212,Neutral
"VIATRIS SHAREHOLDER NOTICE: Securities Litigation Partner James  ( Josh )  Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options",https://www.prnewswire.com/news-releases/viatris-shareholder-notice-securities-litigation-partner-james-josh-wilson-encourages-investors-who-suffered-losses-exceeding-100-000-in-viatris-to-contact-him-directly-to-discuss-their-options-301861327.html,2023-06-24 11:00:00,VIATRIS SHAREHOLDER NOTICE: Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who ... PR ...,VTRS,0.633079,0.211823,Somewhat-Bullish
"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS",https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-viatris-inc-of-class-action-lawsuit-and-upcoming-deadline--vtrs-301861367.html,2023-06-24 01:57:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of ... PR ...",VTRS,0.77735,0.115338,Neutral
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc.  ( VTRS )  - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/06/g32985449/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-agains,2023-06-23 14:41:00,"LOS ANGELES, June 23, 2023 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( ""GPM"" ) reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Viatris Inc. ( ""Viatris"" or the ...",VTRS,0.516883,0.124951,Neutral
"DEADLINE ALERT for BYND, DIS, STEM, VTRS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - Beyond Meat  ( NASDAQ:BYND ) , Walt Disney  ( NYSE:DIS ) ",https://www.benzinga.com/pressreleases/23/06/g32977111/deadline-alert-for-bynd-dis-stem-vtrs-law-offices-of-howard-g-smith-reminds-investors-of-class-act,2023-06-22 21:24:04,"BENSALEM, Pa., June 22, 2023 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.168785,0.063515,Neutral
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g32970931/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-06-22 16:19:00,"LOS ANGELES, June 22, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
Benzodiazepine APIs Market Projected to Hit USD652.8 Mn by 2031 with a 3.6% CAGR: TMR Report,https://www.benzinga.com/pressreleases/23/06/g32961532/benzodiazepine-apis-market-projected-to-hit-usd652-8-mn-by-2031-with-a-3-6-cagr-tmr-report,2023-06-22 09:30:00,"Wilmington, Delaware, United States, June 22, 2023 ( GLOBE NEWSWIRE ) -- In 2022, the benzodiazepine APIs market was estimated to be worth US$ 472.8 million. It is expected to grow at a 3.6% CAGR from 2023 to 2031, reaching more than US$ 652.8 million by the end of 2031.",VTRS,0.039878,-0.030759,Neutral
"ROSEN, A LONGSTANDING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32959017/rosen-a-longstanding-law-firm-encourages-viatris-inc-investors-to-secure-counsel-before-important-,2023-06-22 01:20:00,"NEW YORK, June 21, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead ...",VTRS,0.544495,0.095628,Neutral
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference - Ocuphire Pharma  ( NASDAQ:OCUP ) ,https://www.benzinga.com/pressreleases/23/06/g32943759/ocuphire-announces-late-breaking-presentation-on-apx3330-zeta-1-clinical-data-at-american-diabetes,2023-06-21 12:00:00,"FARMINGTON HILLS, Mich., June 21, 2023 ( GLOBE NEWSWIRE ) -- Ocuphire Pharma, Inc. OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H.",VTRS,0.049019,-0.072676,Neutral
"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",https://www.prnewswire.com/news-releases/rosen-a-leading-investor-rights-law-firm-encourages-viatris-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action--vtrs-301855564.html,2023-06-20 21:45:00,"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel ... PR ...",VTRS,0.612343,0.229265,Somewhat-Bullish
"Viatris Inc.  ( VTRS )  Class Action Lawsuit Filed on Behalf of Investors - Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32913834/viatris-inc-vtrs-class-action-lawsuit-filed-on-behalf-of-investors-nationally-ranked-investors-rig,2023-06-19 16:26:47,"ATLANTA, June 19, 2023 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC reminds investors that a class action lawsuit has been filed against Viatris Inc. ( ""Viatris,"" or ""the Company"" ) VTRS. The lawsuit alleges Viatris made materially false and/or misleading statements and/or failed to disclose ...",VTRS,0.722509,0.12963,Neutral
"C-SUITE EXECUTIVES OF COCA-COLA, FINE HYGIENIC HOLDING, CIGNA HEALTHCARE, BIC AND VIATRIS TO LEAD AT 2023 MIDDLE EAST EDITION OF BREAK THE CEILING TOUCH THE SKY®",https://www.prnewswire.com/ae/news-releases/c-suite-executives-of-coca-cola-fine-hygienic-holding-cigna-healthcare-bic-and-viatris-to-lead-at-2023-middle-east-edition-of-break-the-ceiling-touch-the-sky-301853893.html,2023-06-19 06:00:00,"C-SUITE EXECUTIVES OF COCA-COLA, FINE HYGIENIC HOLDING, CIGNA HEALTHCARE, BIC AND VIATRIS TO ... PR ...",VTRS,0.072545,0.173719,Somewhat-Bullish
Warren Buffett Owns These 5 High-Yield Dividend Stocks. Should You?,https://www.fool.com/investing/2023/06/18/warren-buffett-owns-these-5-high-yield-dividend-st/,2023-06-18 09:50:00,"Not all of these high-yield stocks are great picks for investors now, but several of them are.",VTRS,0.286193,0.135029,Neutral
"VIATRIS SHAREHOLDER NOTICE: Securities Litigation Partner James  ( Josh )  Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options",https://www.prnewswire.com/news-releases/viatris-shareholder-notice-securities-litigation-partner-james-josh-wilson-encourages-investors-who-suffered-losses-exceeding-100-000-in-viatris-to-contact-him-directly-to-discuss-their-options-301853531.html,2023-06-17 11:00:00,VIATRIS SHAREHOLDER NOTICE: Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who ... PR ...,VTRS,0.633079,0.211823,Somewhat-Bullish
"Pomerantz Law Firm Announces the Filing of a Class Action Against Viatris, Inc. and Certain Officers - VTRS",https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-viatris-inc-and-certain-officers--vtrs-301853598.html,2023-06-17 03:46:00,"NEW YORK, June 16, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ( ""Viatris"" or the ""Company"" ) ( NASDAQ: VTRS ) , and certain officers.",VTRS,0.77735,0.115338,Neutral
"ROSEN, A LEADING AND RANKED FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32903693/rosen-a-leading-and-ranked-firm-encourages-viatris-inc-investors-with-losses-to-secure-counsel-bef,2023-06-16 23:31:00,"NEW YORK, June 16, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead plaintiff ...",VTRS,0.544495,0.092125,Neutral
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g32877671/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-06-15 15:32:00,"LOS ANGELES, June 15, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
"DEADLINE ALERT for BYND, DIS, STEM, VTRS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - Beyond Meat  ( NASDAQ:BYND ) , Walt Disney  ( NYSE:DIS ) ",https://www.benzinga.com/pressreleases/23/06/g32861383/deadline-alert-for-bynd-dis-stem-vtrs-law-offices-of-howard-g-smith-reminds-investors-of-class-act,2023-06-14 18:01:43,"BENSALEM, Pa., June 14, 2023 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.168785,0.063515,Neutral
VIATRIS INC.  ( NASDAQ: VTRS )  SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/06/g32829380/viatris-inc-nasdaq-vtrs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-of,2023-06-13 05:45:00,"Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at ( 212 ) 951-2030 or pallocco@bernlieb.com to discuss your rights.",VTRS,0.585052,0.161531,Somewhat-Bullish
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32827422/hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors-with-substantial-losses-t,2023-06-12 22:06:09,"SAN FRANCISCO, June 12, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.310824,Somewhat-Bullish
"ROSEN, NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32809225/rosen-national-trial-counsel-encourages-viatris-inc-investors-with-losses-to-secure-counsel-before,2023-06-11 17:03:00,"NEW YORK, June 11, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead ...",VTRS,0.544495,0.095628,Neutral
"VIATRIS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James  ( Josh )  Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options",https://www.prnewswire.com/news-releases/viatris-shareholder-action-reminder-securities-litigation-partner-james-josh-wilson-encourages-investors-who-suffered-losses-exceeding-100-000-in-viatris-to-contact-him-directly-to-discuss-their-options-301847458.html,2023-06-10 11:00:00,VIATRIS SHAREHOLDER ACTION REMINDER: Securities Litigation ... PR ...,VTRS,0.633079,0.211823,Somewhat-Bullish
Viatris Inc.  ( VTRS )  Securities Class Action: Investors Should Contact Robbins LLP for Information About Their Rights - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/06/g32799612/viatris-inc-vtrs-securities-class-action-investors-should-contact-robbins-llp-for-information-abou,2023-06-09 16:50:09,"SAN DIEGO, June 09, 2023 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or entities who purchased otherwise acquired Viatris VTRS common stock between March 1, 2021 and February 25, 2022. Viatris is a global healthcare corporation.",VTRS,0.827318,-0.016422,Neutral
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g32797911/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-06-09 15:20:00,"LOS ANGELES, June 09, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
"[2023-2028] Transdermal Medical Patch Market Size to Hit $10.79 Billion, Globally by 2028 - Exclusive Report by The Insight Partners",https://www.benzinga.com/pressreleases/23/06/g32796568/2023-2028-transdermal-medical-patch-market-size-to-hit-10-79-billion-globally-by-2028-exclusive-re,2023-06-09 14:32:00,"Pune, India, June 09, 2023 ( GLOBE NEWSWIRE ) -- According to our latest study on ""Transdermal Medical Patch Market Size Report, Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Application, and Distribution Channel,"" the market is projected to reach USD 10.79 billion by 2028 ...",VTRS,0.027763,0.06777,Neutral
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit,https://www.prnewswire.com/news-releases/vtrs-investors-have-opportunity-to-lead-viatris-inc-securities-fraud-lawsuit-301846668.html,2023-06-08 22:45:00,VTRS Investors Have Opportunity to Lead Viatris Inc. Securities ... PR ...,VTRS,0.570165,0.218067,Somewhat-Bullish
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys,https://www.fool.com/investing/2023/06/08/these-2-dividend-stocks-yield-5-and-they-arent-ris/,2023-06-08 12:08:00,These stocks are both down 20% in the past year. Now could be the time to load up on them.,VTRS,0.515749,0.432607,Bullish
API manufacturing facility in Bangalore receives GMP certificate: Biocon,https://www.business-standard.com/companies/news/api-manufacturing-facility-in-bangalore-receives-gmp-certificate-biocon-123060800717_1.html,2023-06-08 11:24:22,"Shares of Biocon, on Thursday, fell nearly 1% at Rs 241.40 on ...",VTRS,0.183198,0.137131,Neutral
"ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",https://www.prnewswire.com/news-releases/rosen-skilled-investor-counsel-encourages-viatris-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action--vtrs-301845286.html,2023-06-08 01:24:00,"ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc ... PR ...",VTRS,0.612343,0.229265,Somewhat-Bullish
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS,https://www.benzinga.com/pressreleases/23/06/g32771437/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-viatris-inc-vtr,2023-06-08 00:32:09,"NEW YORK, June 07, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ( ""Viatris"" or the ""Company"" ) VTRS. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",VTRS,0.673559,0.127253,Neutral
Why Is Theravance Bio  ( TBPH )  Down 3.8% Since Last Earnings Report?,https://www.zacks.com/stock/news/2105174/why-is-theravance-bio-tbph-down-38-since-last-earnings-report,2023-06-07 15:30:41,Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.06211,0.114034,Neutral
Why Is Viatris  ( VTRS )  Down 2.4% Since Last Earnings Report?,https://www.zacks.com/stock/news/2105189/why-is-viatris-vtrs-down-24-since-last-earnings-report,2023-06-07 15:30:34,Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.546745,0.17614,Somewhat-Bullish
9 S&P 500 Stocks Are Screaming Buys According To The 'Fed Model',https://www.investors.com/etfs-and-funds/sectors/sp500-nine-stocks-are-screaming-buys-according-to-the-fed-model/,2023-06-07 12:00:00,Why deal with the S&P 500 when savings accounts pay 5%? That's exactly why many rich people are dumping stocks for cash. But the so-called Fed Model points to stocks that might still be worth your while.,VTRS,0.202366,0.158695,Somewhat-Bullish
"ROSEN, A TOP RANKED LAW FIRM, Encourages Viatris Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32749067/rosen-a-top-ranked-law-firm-encourages-viatris-inc-investors-with-losses-exceeding-100k-to-secure-,2023-06-06 22:00:00,"NEW YORK, June 06, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead plaintiff ...",VTRS,0.544495,0.092125,Neutral
How the WHO Foundation Tackles Global Health Crises,https://www.barrons.com/articles/how-the-who-foundation-tackles-global-health-crises-a85edd55,2023-06-06 18:21:00,"Climate change is the greatest threat to human health today and over the next 50 years, says Anil Soni, CEO of the WHO Foundation.",VTRS,0.049221,0.056387,Neutral
NEW CERTIFICATION AIMS TO MITIGATE ANTIMICROBIAL RESISTANCE RISK IN ANTIBIOTIC MANUFACTURING,https://www.prnewswire.com/news-releases/new-certification-aims-to-mitigate-antimicrobial-resistance-risk-in-antibiotic-manufacturing-301840073.html,2023-06-05 12:10:00,NEW CERTIFICATION AIMS TO MITIGATE ANTIMICROBIAL ... PR ...,VTRS,0.030408,0.0,Neutral
Looking for Passive Income at a Decent Price? Buy These 2 Stocks,https://www.fool.com/investing/2023/06/05/looking-passive-income-decent-price-buy-stocks/,2023-06-05 09:05:00,"If you're willing to accept slower growth, there are great bargains awaiting.",VTRS,0.288327,0.172928,Somewhat-Bullish
VIATRIS INC.  ( NASDAQ: VTRS )  SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/06/g32707821/viatris-inc-nasdaq-vtrs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-of,2023-06-05 05:45:00,"Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at ( 212 ) 951-2030 or pallocco@bernlieb.com to discuss your rights.",VTRS,0.585052,0.161531,Somewhat-Bullish
"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Viatris, Inc.  ( VTRS )  and Encourages Investors with Significant Losses to Contact the Firm - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32706285/kessler-topaz-meltzer-check-llp-announces-a-securities-fraud-class-action-lawsuit-filed-against-vi,2023-06-04 14:56:00,"RADNOR, Pa., June 04, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. ( ...",VTRS,0.728579,0.063025,Neutral
"Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Viatris, Inc.  ( VTRS )  Investors and Encourages Investors to Contact the Firm Before July 14, 2023 - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/06/g32700193/kirby-mcinerney-llp-reminds-investors-that-a-class-action-lawsuit-has-been-filed-on-behalf-of-viat,2023-06-02 20:54:42,"NEW YORK, June 02, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S.",VTRS,0.630286,0.261394,Somewhat-Bullish
Why The Biotech Buying Bonanza Will Likely Continue,https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/,2023-06-02 17:17:00,Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...,VTRS,0.031529,0.0,Neutral
Autoinjectors Market worth $1.7 billion | MarketsandMarkets,https://www.prnewswire.com/news-releases/autoinjectors-market-worth-1-7-billion--marketsandmarkets-301840949.html,2023-06-02 17:00:00,"CHICAGO, June 2, 2023 /PRNewswire/ -- The autoinjectors industry is set to experience significant growth in the near future as a result of several factors. With the rise in chronic diseases and the increasing need for self-administration of medication, autoinjectors have emerged as a convenient ...",VTRS,0.021937,0.013872,Neutral
"DEADLINE ALERT for VTRS, CRL, and VIRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Charles River  ( NYSE:CRL ) , Virtu Finl  ( NASDAQ:VIRT ) ",https://www.benzinga.com/pressreleases/23/06/g32694792/deadline-alert-for-vtrs-crl-and-virt-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-ac,2023-06-02 16:48:00,"LOS ANGELES, June 02, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.",VTRS,0.231884,0.018994,Neutral
"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32639763/rosen-a-leading-investor-rights-law-firm-encourages-viatris-inc-investors-with-losses-to-secure-co,2023-05-31 00:18:00,"NEW YORK, May 30, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead plaintiff ...",VTRS,0.545618,0.109231,Neutral
Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023,https://www.prnewswire.com/news-releases/viatris-named-to-usa-todays-inaugural-list-of-americas-climate-leaders-2023-301837080.html,2023-05-30 13:00:00,Viatris Named to USA Today's Inaugural List of America's Climate ... PR ...,VTRS,0.657184,0.395615,Bullish
"Eye Care Sector Sees Several Large Acquisitions - Could This Ticker Be On Route For The Next Big Acquisition? - IVERIC bio  ( NASDAQ:ISEE ) , Astellas Pharma  ( OTC:ALPMF ) ",https://www.benzinga.com/markets/penny-stocks/23/05/32623074/eye-care-sector-sees-several-large-acquisitions-could-this-ticker-be-on-route-for-the-next-b,2023-05-30 12:43:37,"The Japanese healthcare company Astellas Pharma, Inc. ALPMF recently announced its acquisition of the biopharmaceutical company Iveric Bio ISEE. Iveric Bio's focus is on developing innovative treatments for eye diseases.",VTRS,0.246167,0.123822,Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS,https://www.benzinga.com/pressreleases/23/05/g32609002/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-viatris-inc-vtr,2023-05-28 03:14:20,"NEW YORK, May 27, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ( ""Viatris"" or the ""Company"" ) VTRS. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",VTRS,0.666827,0.126661,Neutral
"VTRS CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Viatris Inc.",https://markets.businessinsider.com/news/stocks/vtrs-class-action-announcement-kessler-topaz-meltzer-check-llp-announces-securities-class-action-lawsuit-filed-against-viatris-inc.-1032355366,2023-05-27 15:02:00,"Radnor, Pennsylvania-- ( Newsfile Corp. - May 27, 2023 ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. ...",VTRS,0.630514,0.070078,Neutral
"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Viatris Inc.  ( VTRS )  - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32600494/kessler-topaz-meltzer-check-llp-announces-a-securities-fraud-class-action-filed-against-viatris-in,2023-05-26 17:30:00,"RADNOR, Pa., May 26, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. ( ...",VTRS,0.572037,0.063077,Neutral
VIATRIS INC.  ( NASDAQ: VTRS )  SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/05/g32589303/viatris-inc-nasdaq-vtrs-shareholder-class-action-alert-bernstein-liebhard-llp-announces-that-a-sec,2023-05-26 05:45:00,"Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at ( 212 ) 951-2030 or pallocco@bernlieb.com to discuss your rights.",VTRS,0.628304,0.095185,Neutral
"ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32582000/rosen-national-investor-counsel-encourages-viatris-inc-investors-with-losses-to-secure-counsel-bef,2023-05-25 18:22:57,"NEW YORK, May 25, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) , of the important July 14, 2023 lead plaintiff ...",VTRS,0.545618,0.116134,Neutral
India's Biocon Biologics says biosimilars put revenue on $1 bln trajectory,https://www.reuters.com/business/healthcare-pharmaceuticals/indias-biocon-biologics-says-biosimilars-put-revenue-1-bln-trajectory-2023-05-24/,2023-05-24 22:33:00,India's Biocon Biologics says biosimilars put revenue on $1 bln ... ...,VTRS,0.239305,0.101452,Neutral
Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe,https://www.business-standard.com/companies/interviews/we-are-seeing-huge-demand-for-insulin-products-biocon-biologics-md-ceo-123052400868_1.html,2023-05-24 16:18:42,Biocon IPO after integration of Viatris market: MD & CEO Shreehas ... Business Standard ...,VTRS,0.360752,0.0,Neutral
"Biocon Q4FY23 profit up 31.3% at Rs 313.20 crore on robust sales, beats estimates | The Financial Express",https://www.financialexpress.com/industry/biocon-q4fy23-profit-up-31-3-at-rs-31320-crore-on-robust-sales-beats-estimates/3100000/,2023-05-24 07:52:49,Biocon Q4FY23 profit up 31.3% at Rs 313.20 crore on robust sales ... The Financial Express ...,VTRS,0.142565,0.162916,Somewhat-Bullish
Viatris Inc.  ( VTRS )  Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/05/g32537912/viatris-inc-vtrs-shareholder-notice-robbins-llp-reminds-investors-of-class-action-against-viatris-,2023-05-23 18:14:42,"SAN DIEGO, May 23, 2023 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or entities who purchased otherwise acquired Viatris VTRS common stock between March 1, 2021 and February 25, 2022. Viatris is a global healthcare corporation.",VTRS,0.827318,-0.020538,Neutral
"Biocon Q4 results: Net profit rises 31% to Rs 313 cr, revenue up 57%",https://www.business-standard.com/companies/results/biocon-q4-results-net-profit-rises-31-to-rs-313-cr-revenue-up-57-123052301133_1.html,2023-05-23 16:07:12,"For the entire financial year, the company's net profit saw a decline of 29 per cent to Rs 462.7 crore, as compared to Rs 648.4 crore in ...",VTRS,0.203215,0.163583,Somewhat-Bullish
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Viatris  ( VTRS )  Investors to Filing of Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32512088/hagens-berman-national-trial-attorneys-alerts-viatris-vtrs-investors-to-filing-of-securities-fraud,2023-05-22 16:02:29,"SAN FRANCISCO, May 22, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.310824,Somewhat-Bullish
Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year,https://www.prnewswire.com/news-releases/robert-j-coury-to-transition-from-executive-chairman-of-viatris-to-chairman-emeritus-and-senior-strategic-advisor-to-the-board-and-management-at-the-end-of-the-year-301830676.html,2023-05-22 11:40:00,Robert J. Coury to Transition from Executive Chairman of Viatris to ... PR ...,VTRS,0.559666,0.45544,Bullish
Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors,https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-leo-groothuis-to-companys-board-of-directors-301830418.html,2023-05-22 10:30:00,Viatris Announces Appointment of Leo Groothuis to Company's ... PR ...,VTRS,0.691734,0.270678,Somewhat-Bullish
"ACCENTURE, BIC TO LEAD AFRICA'S MOST INSPIRATIONAL WOMEN IN LEADERSHIP AT 2023 AFRICA BREAK THE CEILING TOUCH THE SKY® SUMMIT.",https://www.prnewswire.com/news-releases/accenture-bic-to-lead-africas-most-inspirational-women-in-leadership-at-2023-africa-break-the-ceiling-touch-the-sky-summit-301830566.html,2023-05-22 08:45:00,"ACCENTURE, BIC TO LEAD AFRICA'S MOST INSPIRATIONAL ... PR ...",VTRS,0.08687,0.022644,Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS,https://www.benzinga.com/pressreleases/23/05/g32501400/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-viatris-inc-vtr,2023-05-21 22:30:32,"NEW YORK, May 21, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ( ""Viatris"" or the ""Company"" ) VTRS. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",VTRS,0.673559,0.127253,Neutral
"ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32490572/rosen-a-globally-respected-law-firm-encourages-viatris-inc-investors-with-losses-to-secure-counsel,2023-05-19 17:11:00,"NEW YORK, May 19, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Viatris Inc. VTRS between March 1, 2021 and February 25, 2022, both dates inclusive ( the ""Class Period"" ) ...",VTRS,0.547877,0.061869,Neutral
"ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",https://www.prnewswire.com/news-releases/rosen-trusted-national-trial-counsel-encourages-viatris-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action--vtrs-301828844.html,2023-05-18 19:29:00,"ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages ... PR ...",VTRS,0.616089,0.191855,Somewhat-Bullish
Viatris Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information,https://markets.businessinsider.com/news/stocks/viatris-sued-for-securities-law-violations-investors-should-contact-block-leviton-for-more-information-1032337785,2023-05-18 14:22:00,Viatris Sued for Securities Law Violations. Investors Should Contact Block & Leviton for More Information ...,VTRS,0.661658,0.045875,Neutral
VTRS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/05/g32466745/vtrs-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-viatris-inc-investors-with-su,2023-05-18 13:48:38,"SAN DIEGO, May 18, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. VTRS common stock between March 1, 2021 and February 25, 2022, inclusive ( the ""Class Period"" ) have until July 14, 2023 to seek appointment as ...",VTRS,0.909841,0.174737,Somewhat-Bullish
"It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?",https://www.fool.com/investing/2023/05/18/cheap-pays-big-dividend-but-is-viatris-stock/,2023-05-18 10:28:00,It looks more appealing in theory than it is in terms of its actual performance.,VTRS,0.469935,0.242106,Somewhat-Bullish
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc.  ( VTRS )  - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/pressreleases/23/05/g32450673/gainey-mckenna-egleston-announces-a-class-action-lawsuit-has-been-filed-against-viatris-inc-vtrs,2023-05-17 17:06:48,"NEW YORK, May 17, 2023 ( GLOBE NEWSWIRE ) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania on behalf of all persons or entities who purchased the securities of Viatris Inc. ( ...",VTRS,0.436009,0.253998,Somewhat-Bullish
"Class Action Lawsuit Filed on Behalf of Viatris Inc.  ( VTRS )  Investors - Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32450451/class-action-lawsuit-filed-on-behalf-of-viatris-inc-vtrs-investors-nationally-ranked-investors-rig,2023-05-17 16:58:17,"ATLANTA, May 17, 2023 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Viatris Inc. ( ""Viatris,"" or ""the Company"" ) VTRS. The lawsuit alleges Viatris made materially false and/or misleading statements and/or failed to disclose ...",VTRS,0.722509,0.12963,Neutral
3 High-Yield Dividend Stocks You Probably Didn't Know Warren Buffett Owns,https://www.fool.com/investing/2023/05/17/high-yield-dividend-stocks-warren-buffett-owns/,2023-05-17 09:50:00,Buffett has a few cards up his sleeve with these stocks.,VTRS,0.433877,0.244478,Somewhat-Bullish
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Viatris  ( VTRS )  Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/05/g32436136/hagens-berman-national-trial-attorneys-encourages-viatris-vtrs-investors-with-substantial-losses-t,2023-05-16 22:41:52,"SAN FRANCISCO, May 16, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Viatris Inc. VTRS investors who suffered substantial losses to submit your losses now. Class Period: Mar. 1, 2021 - Feb. 25, 2022Lead Plaintiff Deadline: July 14, 2023Visit: www.hbsslaw.com/investor-fraud/VTRS Contact An ...",VTRS,0.679118,0.310824,Somewhat-Bullish
"Intrauterine Contraceptive Devices  ( IUD )  Market size to grow by USD 965.49 million between 2022 and 2027; AbbVie Inc., Bayer AG, DKT International among others, identified as key vendors - Technavio",https://www.prnewswire.com/news-releases/intrauterine-contraceptive-devices-iud-market-size-to-grow-by-usd-965-49-million-between-2022-and-2027-abbvie-inc-bayer-ag-dkt-international-among-others-identified-as-key-vendors--technavio-301822563.html,2023-05-15 00:15:00,Intrauterine Contraceptive Devices ( IUD ) Market size to grow by ... PR ...,VTRS,0.05257,0.050714,Neutral
Theravance's  ( TBPH )  Q1 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2092291/theravances-tbph-q1-earnings-and-revenues-miss-estimates,2023-05-09 13:24:00,Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.,VTRS,0.456544,0.362591,Bullish
"S&P 500 Stocks: Chip Giant Is Big Winner, Surging Above Early Entry",https://www.investors.com/news/sp-500-stocks-carnival-amd-are-big-winners-today/,2023-05-08 20:22:00,"S&P 500 Stocks: Carnival, AMD Are Big Winners Today | Investor's ... Investor's Business Daily ...",VTRS,0.340915,-0.022619,Neutral
"Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-first-quarter-2023-financial-results-and-provides-business-update-301818591.html,2023-05-08 20:05:00,"Theravance Biopharma, Inc. Reports First Quarter 2023 Financial ... PR ...",VTRS,0.225869,0.135997,Neutral
"Viatris  ( VTRS )  Q1 Earnings Beat, Revenues Miss Estimates",https://www.zacks.com/stock/news/2091731/viatris-vtrs-q1-earnings-beat-revenues-miss-estimates,2023-05-08 16:48:00,Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.,VTRS,0.677342,-0.056636,Neutral
"Stocks making the biggest moves midday: Berkshire Hathaway, Catalent, Tyson Foods, Zscaler and more",https://www.cnbc.com/2023/05/08/stocks-making-the-biggest-moves-midday-brka-ctlt-tsn-zs.html,2023-05-08 16:35:19,These are the stocks posting the largest moves in midday trading.,VTRS,0.117486,0.071812,Neutral
Viatris Eyes Midpoint Of FY23 Guidance Post Mixed Q1 Performance - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/news/earnings/23/05/32264612/viatris-eyes-midpoint-of-fy23-guidance-post-mixed-q1-performance,2023-05-08 15:40:58,"Viatris Inc VTRS reported Q1 FY23 sales of $3.73 billion, down 2% on a divestiture-adjusted operational basis, below the consensus of $3.81 billion. Brands performed in line with expectations, driven by products such as Dymista, Celebrex, and Norvasc.",VTRS,0.659096,0.352593,Bullish
Viatris reaffirms 2023 sales forecast on strong demand for newer drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-reaffirms-2023-sales-forecast-strong-demand-newer-drugs-2023-05-08/,2023-05-08 14:04:00,"May 8 ( Reuters ) - Viatris Inc ( VTRS.O ) reaffirmed its full-year revenue forecast on Monday and said it was on track to achieve about $500 million in annual sales from its newly launched products, sending its shares up nearly 2% in early trading.",VTRS,0.639616,0.234547,Somewhat-Bullish
Viatris  ( VTRS )  Tops Q1 Earnings Estimates,https://www.zacks.com/stock/news/2091385/viatris-vtrs-tops-q1-earnings-estimates,2023-05-08 12:25:04,"Viatris (VTRS) delivered earnings and revenue surprises of 13.04% and 1.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.405651,0.08563,Neutral
"Stocks making the biggest premarket moves: PacWest, Berkshire Hathaway, American Airlines, AMC and more",https://www.cnbc.com/2023/05/08/stocks-making-the-biggest-premarket-moves-.html,2023-05-08 12:04:54,These are the stocks posting the largest moves in the premarket.,VTRS,0.163354,0.137904,Neutral
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1],https://www.prnewswire.com/news-releases/viatris-reports-strong-financial-and-operational-results-for-first-quarter-2023-and-reaffirms-full-year-2023-guidance-ranges1-301817849.html,2023-05-08 10:59:00,Viatris Reports Strong Financial and Operational Results for First ... PR ...,VTRS,0.287245,0.194146,Somewhat-Bullish
VTRS ALERT: The Law Offices of Vincent Wong Investigate Viatris Inc. for Potential Violations of Securities Laws,https://www.prnewswire.com/news-releases/vtrs-alert-the-law-offices-of-vincent-wong-investigate-viatris-inc-for-potential-violations-of-securities-laws-301815563.html,2023-05-08 09:45:00,VTRS ALERT: The Law Offices of Vincent Wong Investigate Viatris ... PR ...,VTRS,0.909909,-0.122691,Neutral
Epilepsy Drugs Market Is Expected to Reach $9.8 Billion by 2032: Allied Market Research,https://www.benzinga.com/pressreleases/23/05/g32241720/epilepsy-drugs-market-is-expected-to-reach-9-8-billion-by-2032-allied-market-research,2023-05-05 15:16:17,"Portland, OR, May 05, 2023 ( GLOBE NEWSWIRE ) -- According to the report published by Allied Market Research, the global epilepsy drugs market generated $7 billion in 2022, and is estimated to reach $9.8 billion by 2032, witnessing a CAGR of 3.5% from 2023 to 2032.",VTRS,0.036756,0.063953,Neutral
VTRS FRAUD ALERT: Jakubowitz Law is Investigating Viatris Inc. in Connection with Potential Violations of Federal Securities Laws,https://www.prnewswire.com/news-releases/vtrs-fraud-alert-jakubowitz-law-is-investigating-viatris-inc-in-connection-with-potential-violations-of-federal-securities-laws-301815279.html,2023-05-05 09:45:00,VTRS FRAUD ALERT: Jakubowitz Law is Investigating Viatris Inc. in ... PR ...,VTRS,0.838487,-0.049549,Neutral
Viatris  ( VTRS )  to Report Q1 Earnings: What's in the Offing?,https://www.zacks.com/stock/news/2090311/viatris-vtrs-to-report-q1-earnings-whats-in-the-offing,2023-05-04 16:17:00,"Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.",VTRS,0.693986,0.269095,Somewhat-Bullish
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of an Investigation and Potential Class Action Lawsuit -  ( NasdaqGS: VTRS ) ,https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-viatris-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaqgs-vtrs-301815067.html,2023-05-03 21:23:00,INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders ... PR ...,VTRS,0.742397,-0.102491,Neutral
Bausch + Lomb  ( BLCO )  Q1 Earnings Lag Estimates,https://www.zacks.com/stock/news/2088817/bausch-lomb-blco-q1-earnings-lag-estimates,2023-05-03 12:15:13,"Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.20698,0.0,Neutral
Viatris  ( VTRS )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2087739/viatris-vtrs-gains-as-market-dips-what-you-should-know,2023-05-01 22:15:18,"Viatris (VTRS) closed the most recent trading day at $9.36, moving +0.32% from the previous trading session.",VTRS,0.572194,0.152723,Somewhat-Bullish
"VTRS INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/04/g32079177/vtrs-investor-alert-levi-korsinsky-llp-reminds-investors-of-an-investigation-involving-possible-se,2023-04-28 11:00:00,"NEW YORK, April 28, 2023 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ( ""Viatris"" or the ""Company"" ) VTRS concerning possible violations of federal securities laws.",VTRS,0.722509,-0.038904,Neutral
"Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks",https://moneymorning.com/investing/want-to-collect-1100-in-dividends-invest-20000-in-these-2-stocks/,2023-04-27 13:45:00,"If you have $20,000 or more in savings that you can afford to invest in stocks, you may want to consider putting that in some high-yielding investments that can provide you with some great recurring income.",VTRS,0.699089,0.254304,Somewhat-Bullish
"Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks",https://www.fool.com/investing/2023/04/27/want-to-collect-1000-in-dividends-invest-20000-in/,2023-04-27 13:45:00,"There's a bit of risk with these stocks, but they should prove reliable in generating high dividend payments for your portfolio.",VTRS,0.591449,0.221353,Somewhat-Bullish
Icon PLC  ( ICLR )  Q1 Earnings and Revenues Lag Estimates,https://www.zacks.com/stock/news/2085531/icon-plc-iclr-q1-earnings-and-revenues-lag-estimates,2023-04-26 22:55:08,"Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.205807,0.0,Neutral
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,https://www.zacks.com/stock/news/2084801/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now,2023-04-26 12:50:06,The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.,VTRS,0.329992,0.401637,Bullish
"The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health",https://www.zacks.com/stock/news/2084670/the-zacks-analyst-blog-highlights-humana-viatris-agilon-health-and-cano-health,2023-04-26 09:46:00,"Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.",VTRS,0.272408,0.297201,Somewhat-Bullish
Viatris  ( VTRS )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2084605/viatris-vtrs-dips-more-than-broader-markets-what-you-should-know,2023-04-25 22:15:11,"Viatris (VTRS) closed the most recent trading day at $9.18, moving -1.61% from the previous trading session.",VTRS,0.655281,0.066455,Neutral
Ocuphire  ( OCUP )  to Report Q1 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2084490/ocuphire-ocup-to-report-q1-earnings-whats-in-the-cards,2023-04-25 16:55:00,"Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.",VTRS,0.245339,0.166896,Somewhat-Bullish
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates,https://www.zacks.com/stock/news/2084314/4-healthcare-stocks-poised-to-beat-q1-earnings-estimates,2023-04-25 14:52:00,"Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).",VTRS,0.252987,0.320002,Somewhat-Bullish
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting,https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-to-highlight-latest-results-of-multiple-sclerosis-research-at-american-academy-of-neurology-75th-annual-meeting-301804983.html,2023-04-24 11:00:00,Viatris and Mapi Pharma to Highlight Latest Results of Multiple ... PR ...,VTRS,0.591449,0.243464,Somewhat-Bullish
A Bearish Sign Appears On Viatris's Chart - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/markets/23/04/31916789/a-bearish-sign-appears-on-viatriss-chart,2023-04-20 14:47:34,"If history is any guide, there may be trouble ahead for shares of Viatris VTRS. A so-called ""death cross"" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",VTRS,0.570165,-0.461617,Bearish
Viatris  ( VTRS )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2080767/viatris-vtrs-stock-sinks-as-market-gains-what-you-should-know,2023-04-18 22:15:22,"In the latest trading session, Viatris (VTRS) closed at $9.88, marking a -0.3% move from the previous day.",VTRS,0.604787,0.148301,Neutral
"Overview Of Value Stocks In The Healthcare Sector - AMN Healthcare Services  ( NYSE:AMN ) , Celularity  ( NASDAQ:CELU ) , Intercure  ( NASDAQ:INCR ) , Viatris  ( NASDAQ:VTRS ) , BioNTech  ( NASDAQ:BNTX ) ",https://www.benzinga.com/news/23/04/31833112/overview-of-value-stocks-in-the-healthcare-sector,2023-04-17 14:43:06,"A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the ...",VTRS,0.186738,0.093898,Neutral
Wall Street Thinks These 2 Value Stocks Could Soar,https://www.fool.com/investing/2023/04/17/wall-street-thinks-these-2-value-stocks-could-soar/,2023-04-17 11:15:00,These two companies could produce significant upside for shareholders in the next 12 months.,VTRS,0.47452,0.155381,Somewhat-Bullish
"1 ""Safe"" Stock to Avoid and 1 to Consider Buying in April",https://www.fool.com/investing/2023/04/15/1-safe-stock-to-avoid-and-1-to-consider-buying-in/,2023-04-15 12:56:00,There's more to the concept of safety than having a business model that looks safe.,VTRS,0.264515,0.182512,Somewhat-Bullish
"VTRS INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc. - Viatris  ( NASDAQ:VTRS ) ",https://www.benzinga.com/pressreleases/23/04/g31815754/vtrs-investor-alert-levi-korsinsky-llp-notifies-investors-of-an-investigation-involving-possible-s,2023-04-14 22:00:10,"NEW YORK, April 14, 2023 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ( ""Viatris"" or the ""Company"" ) VTRS concerning possible violations of federal securities laws.",VTRS,0.733479,-0.039155,Neutral
"Acne Drugs Market size to grow by USD 907.11 million from 2022 to 2027, Driven by the emergence of improved diagnostic modalities - Technavio",https://www.prnewswire.com/news-releases/acne-drugs-market-size-to-grow-by-usd-907-11-million-from-2022-to-2027--driven-by-the-emergence-of-improved-diagnostic-modalities---technavio-301795679.html,2023-04-14 03:30:00,Acne Drugs Market size to grow by USD 907.11 million from 2022 to ... PR ...,VTRS,0.025325,0.034283,Neutral
Here's How You Can Collect $100 in Dividends Every Month,https://www.fool.com/investing/2023/04/05/how-you-can-collect-100-in-dividends-every-month/,2023-04-05 14:23:00,These dividend stocks can be excellent sources of recurring cash flow for years.,VTRS,0.299478,0.224106,Somewhat-Bullish
The Cracks Are Starting To Show In The Adderall Shortage,https://www.investors.com/news/technology/teva-stock-what-we-know-and-do-not-about-the-adderall-shortage/,2023-04-05 12:00:00,"Teva Stock: What We Know, And Don't, About The Adderall Shortage Investor's Business Daily ...",VTRS,0.034332,-0.022222,Neutral
'Biocon Biologics will exit FY23 at a $1-billion trajectory' | The Financial Express,https://www.financialexpress.com/industry/biocon-biologics-will-exit-fy23-at-a-1-billion-trajectory/3029281/,2023-03-31 20:45:00,'Biocon Biologics will exit FY23 at a $1-billion trajectory' The Financial Express ...,VTRS,0.382925,0.335696,Somewhat-Bullish
Which Is the Better Dividend Stock: Viatris or Apple?,https://www.fool.com/investing/2023/03/31/which-is-the-better-dividend-stock-viatris-or-appl/,2023-03-31 12:00:00,"One has a higher dividend yield, but there's more to the story.",VTRS,0.620548,0.290914,Somewhat-Bullish
"Top Stories Thursday, Mar. 30: Microsoft To Place Ads In ChatGPT Powered Bing Search, Netflix Preps For Big Transition Into TV Gaming, Coinbase Says US 1M Tech Jobs At Risk",https://www.benzinga.com/general/biotech/23/03/31581441/coinbase-says-us-1m-tech-jobs-at-risk-microsoft-to-place-ads-in-chatgpt-powered-bing-search-netfl,2023-03-30 12:53:47,"Cryptocurrency exchange Coinbase Inc COIN says that one million tech jobs are at risk of being outsourced to other countries. Coinbase said as ""the U.S. goes down a path of regulatory uncertainty,"" the EU, U.K., UAE, Hong Kong, Singapore, Australia, and Japan are all creating ""environments for ...",VTRS,0.107656,0.004393,Neutral
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/general/biotech/23/03/31578765/viatris-among-three-companies-licensed-to-make-gskpfizer-backed-long-acting-hiv-prevention-drug,2023-03-30 12:16:00,"ViiV Healthcare and Medicines Patent Pool ( MPP ) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc VTRS - through its subsidiary Mylan - to manufacture generic versions of cabotegravir long-acting ( LA ) for HIV pre-exposure prophylaxis ( PrEP ) .",VTRS,0.377142,0.010421,Neutral
GSK licenses companies to make cheap copies of HIV prevention drug,https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-licenses-companies-make-cheap-copies-hiv-prevention-drug-2023-03-30/,2023-03-30 06:02:00,"LONDON, March 30 ( Reuters ) - British drugmaker GSK ( GSK.L ) has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.",VTRS,0.1331,0.09493,Neutral
Theravance Bio  ( TBPH )  Down 2% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2071951/theravance-bio-tbph-down-2-since-last-earnings-report-can-it-rebound,2023-03-29 15:30:27,Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.066047,0.188526,Somewhat-Bullish
Why Is Viatris  ( VTRS )  Down 16.4% Since Last Earnings Report?,https://www.zacks.com/stock/news/2071953/why-is-viatris-vtrs-down-164-since-last-earnings-report,2023-03-29 15:30:27,Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,VTRS,0.570165,0.166847,Somewhat-Bullish
Granules India gets USFDA nod for Gabapentin Tablets; share price falls,https://www.moneycontrol.com/news/business/stocks/granules-india-gets-usfda-nod-for-gabapentin-tablets-share-price-falls-10328931.html,2023-03-29 04:28:45,Granules now have a total of 55 ANDA approvals from USFDA.,VTRS,0.182506,0.0,Neutral
Insulin Market Size to Reach USD 30 Bn by 2031 Due to Increase in Incidence of Diabetes | Exclusive Study by TMR,https://www.benzinga.com/pressreleases/23/03/g31536698/insulin-market-size-to-reach-usd-30-bn-by-2031-due-to-increase-in-incidence-of-diabetes-exclusive-,2023-03-28 18:30:00,"Wilmington, Delaware, United States, March 29, 2023 ( GLOBE NEWSWIRE ) -- According to Transparency Market Research, the global insulin market was worth USD 18.5 Bn in 2021. The market is predicted to reach USD 30 Bn by 2031, rising at a CAGR of 4.3% from 2022 to 2031.",VTRS,0.091335,0.137439,Neutral
"3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential",https://www.fool.com/investing/2023/03/26/3-healthcare-spinoffs-worth-a-look-but-1-has-the-b/,2023-03-26 12:45:00,These three spinoffs are already profitable.,VTRS,0.306963,0.199037,Somewhat-Bullish
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.,https://www.fool.com/investing/2023/03/25/i-own-12-high-yield-dividend-stocks-heres-the-best/,2023-03-25 09:52:00,It isn't an easy decision to choose the best among this group of dividend stocks.,VTRS,0.112008,0.233131,Somewhat-Bullish
"Use These 3 Strategies to Make $1,000 in Passive Income Per Year",https://www.fool.com/investing/2023/03/23/use-these-3-strategies-to-make-1000-in-passive-inc/,2023-03-23 10:15:00,It's worth having these approaches in your investor toolkit.,VTRS,0.091509,0.091504,Neutral
"Pfizer Has Another Blockbuster on the Horizon, but That's Not All",https://www.fool.com/investing/2023/03/21/pfizer-has-another-blockbuster-on-the-horizon-but/,2023-03-21 14:00:00,The drugmaker continues to grab headlines for the right reasons.,VTRS,0.057907,0.071002,Neutral
Is Viatris' 5% Dividend Yield Safe?,https://www.fool.com/investing/2023/03/21/is-viatris-5-dividend-yield-safe/,2023-03-21 13:32:47,Should you buy this beaten-down dividend stock?,VTRS,0.716023,0.150841,Somewhat-Bullish
ADT: 3 Stocks to Buy With Less Than $10,https://stocknews.com/news/adt-vtrs-trvg-gs-3-stocks-to-buy-with-less-than-10/,2023-03-20 16:49:02,ADT: 3 Stocks to Buy With Less Than ...,VTRS,0.341857,0.183142,Somewhat-Bullish
Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?,https://www.zacks.com/stock/news/2067786/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe,2023-03-20 10:20:06,Sector ETF report for ...,VTRS,0.1331,0.069906,Neutral
Nasdaq Bear Market: These 3 Stocks Are Trading Below Their Book Values,https://www.fool.com/investing/2023/03/14/nasdaq-bear-market-stocks-trading-below-book/,2023-03-14 10:03:00,Analysts are bullish on all of these stocks.,VTRS,0.334008,0.067996,Neutral
Osteoarthritis therapeutics market to grow at a CAGR of 8.97% from 2022 to 2027: Growth opportunities led by Abbott Laboratories and Alvogen Iceland ehf among others- Technavio,https://www.prnewswire.com/news-releases/osteoarthritis-therapeutics-market-to-grow-at-a-cagr-of-8-97-from-2022-to-2027-growth-opportunities-led-by-abbott-laboratories-and-alvogen-iceland-ehf-among-others--technavio-301761982.html,2023-03-06 19:30:00,Osteoarthritis therapeutics market to grow at a CAGR of 8.97% from ... PR ...,VTRS,0.03878,-0.080555,Neutral
Better Generics Pharmaceutical Stock: Teva or Viatris?,https://www.fool.com/investing/2023/03/05/better-generics-pharmaceutical-stock-teva-or-viatr/,2023-03-05 16:28:00,Both have plans to return to growth.,VTRS,0.413803,0.23092,Somewhat-Bullish
Viatris warns it will stop selling essential drugs in UK without changes to drug pricing agreement,https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-warns-it-will-stop-selling-essential-drugs-uk-without-changes-drug-2023-03-02/,2023-03-02 21:43:59,Viatris warns it will stop selling essential drugs in UK without ... ...,VTRS,0.56217,-0.397407,Bearish
Short Volatility Alert: Viatris Inc - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/23/03/31171333/short-volatility-alert-viatris-inc,2023-03-02 15:03:35,"On Wednesday, shares of Viatris Inc VTRS experienced volatile short activity. After the activity, the stock price went down -0.79% to $11.31. The overall sentiment for VTRS has been Neutral. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong Buy.",VTRS,0.350564,0.017548,Neutral
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise,https://www.fool.com/investing/2023/03/02/undervalued-growth-stocks-with-long-term-prospects/,2023-03-02 12:30:00,There's nothing better than getting a bargain that'll pay off for years.,VTRS,0.251941,0.189262,Somewhat-Bullish
Theravance's  ( TBPH )  Q4 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2059990/theravances-tbph-q4-earnings-and-revenues-miss-estimates,2023-02-28 19:17:00,Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.,VTRS,0.293038,0.108785,Neutral
Pulmonary Arterial Hypertension Market Worth  ( $10.88 Billion by 2028 )  Lead by Asia Pacific Region  ( 6.5% CAGR )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/02/g31091255/pulmonary-arterial-hypertension-market-worth-10-88-billion-by-2028-lead-by-asia-pacific-region-6-5,2023-02-28 14:03:29,"New York, Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Pulmonary Arterial Hypertension Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs [Endothelin Receptor Antagonists ( ERAs ) , Prostacyclin and ...",VTRS,0.021087,0.112619,Neutral
Viatris: Q4 Earnings Snapshot,https://apnews.com/article/earnings-22a59cc7276cb37c2c6edb9fbb77fe2e,2023-02-27 21:40:35,"CANONSBURG, Pa. ( AP ) - CANONSBURG, Pa. ( AP ) - Viatris Inc ( VTRS ) on Monday reported fourth-quarter profit of $1.01 billion. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had net income of 83 cents. Earnings, adjusted for one-time gains and costs, were 69 ...",VTRS,0.866386,0.212762,Somewhat-Bullish
"Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-announces-strategic-actions-and-reports-fourth-quarter--full-year-2022-financial-results-and-business-update-301757052.html,2023-02-27 21:05:00,"Theravance Biopharma, Inc. Announces Strategic Actions and ... PR ...",VTRS,0.146025,0.120812,Neutral
"Viatris'  ( VTRS )  Q4 Earnings In-Line, Revenues Miss Estimates",https://www.zacks.com/stock/news/2059440/viatris-vtrs-q4-earnings-in-line-revenues-miss-estimates,2023-02-27 17:39:00,Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.,VTRS,0.660375,0.073911,Neutral
"Stocks making the biggest moves midday: Union Pacific, Fisker, Tesla, Zillow and more",https://www.cnbc.com/2023/02/27/stocks-making-the-biggest-moves-midday-unp-fsr-tsla-z-and-more.html,2023-02-27 17:11:29,Union Pacific soared on news of a leadership change.,VTRS,0.136499,0.241546,Somewhat-Bullish
Viatris  ( VTRS )  Q4 Earnings: Taking a Look at Key Metrics Versus Estimates,https://www.zacks.com/stock/news/2059358/viatris-vtrs-q4-earnings-taking-a-look-at-key-metrics-versus-estimates,2023-02-27 15:19:00,"While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",VTRS,0.43789,0.113625,Neutral
Viatris names Scott Smith as CEO ahead of planned divestiture of certain businesses,https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-names-scott-smith-ceo-ahead-planned-divestiture-certain-businesses-2023-02-27/,2023-02-27 14:01:00,Viatris names Scott Smith as CEO ahead of planned divestiture of ... ...,VTRS,0.519739,0.173764,Somewhat-Bullish
BioAtla Announces Change in Executive Leadership,https://www.globenewswire.com/news-release/2023/02/27/2616085/0/en/BioAtla-Announces-Change-in-Executive-Leadership.html,2023-02-27 13:07:00,"SAN DIEGO, Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- BioAtla, Inc. ( Nasdaq: BCAB ) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ( CAB ) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott ...",VTRS,0.079524,0.114864,Neutral
2 Dividend Stocks to Buy at a Discounted Price In 2023,https://www.fool.com/investing/2023/02/27/2-dividend-stocks-to-buy-at-a-discounted-price-in/,2023-02-27 13:00:00,Their shares are ripe for getting while the getting is good.,VTRS,0.297301,-0.006583,Neutral
"Stocks making the biggest moves premarket: Best Buy, Seagen, Union Pacific and more",https://www.cnbc.com/2023/02/27/stocks-making-the-biggest-moves-premarket-bby-sgen-unp.html,2023-02-27 12:58:13,Shares of Union Pacific rose 9.5% after the company said CEO Lance Fritz would have a successor named this year.,VTRS,0.27432,0.209418,Somewhat-Bullish
"Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023",https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html,2023-02-27 12:45:00,Viatris Announces Appointment of Scott A. Smith as CEO Effective ... PR ...,VTRS,0.780925,0.506871,Bullish
Biosimilars Market Size Worth  ( $136+ Billion by 2028 )  Lead by Intravenous Segment  ( 36% CAGR )  - Exclusive Research Study by The Insight Partners,https://www.benzinga.com/pressreleases/23/02/g31066933/biosimilars-market-size-worth-136-billion-by-2028-lead-by-intravenous-segment-36-cagr-exclusive-re,2023-02-27 12:39:55,"New York, Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Biosimilars Market Size, Share, Growth, Strategy & Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication ( Cancer, Diabetes, Autoimmune Diseases, and Other Diseases ) , Drug Class ( ...",VTRS,0.088553,0.10367,Neutral
Viatris  ( VTRS )  Matches Q4 Earnings Estimates,https://www.zacks.com/stock/news/2059142/viatris-vtrs-matches-q4-earnings-estimates,2023-02-27 12:25:03,"Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.416844,0.20016,Somewhat-Bullish
"Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/02/31065503/nasdaq-s-p-500-futures-rebound-in-new-trading-week-but-rising-bond-yields-remain-a-risk,2023-02-27 11:47:05,"US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could trigger bargain-hunting-related buying.",VTRS,0.116914,0.0,Neutral
Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance,https://www.prnewswire.com/news-releases/viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-financial-guidance-301756171.html,2023-02-27 11:00:00,Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial ... PR ...,VTRS,0.246904,0.146555,Neutral
"4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates",https://www.zacks.com/stock/news/2057943/4-drug-biotech-stocks-poised-to-beat-q4-earnings-estimates,2023-02-23 12:46:00,"We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.",VTRS,0.046907,0.015914,Neutral
"Teladoc  ( TDOC )  Reports Q4 Loss, Tops Revenue Estimates",https://www.zacks.com/stock/news/2057664/teladoc-tdoc-reports-q4-loss-tops-revenue-estimates,2023-02-22 22:25:09,"Teladoc (TDOC) delivered earnings and revenue surprises of 14.81% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",VTRS,0.210579,0.0,Neutral
Bill Gates buys 3.76% stake in Heineken Holding - filing,https://www.reuters.com/markets/deals/bill-gates-buys-376-stake-heineken-holding-filing-2023-02-22/,2023-02-22 13:07:17,• None INDUS Realty to be taken private in $868 mln deal U.S.-based logistics company INDUS Realty Trust Inc said on Wednesday it would be taken private by affiliates of investment firms Centerbridge Partners and GIC Real Estate in an all-cash deal valued at about $868 million.,VTRS,0.250386,0.164141,Somewhat-Bullish
2 Superb Dividend Stocks to Buy Before the Next Bull Market,https://www.fool.com/investing/2023/02/21/2-superb-dividend-stocks-to-buy-before-the-next-bu/,2023-02-21 13:20:00,There might not be an opportunity to get them for much cheaper than now.,VTRS,0.249106,0.110472,Neutral
Analysts Estimate Viatris  ( VTRS )  to Report a Decline in Earnings: What to Look Out for,https://www.zacks.com/stock/news/2056406/analysts-estimate-viatris-vtrs-to-report-a-decline-in-earnings-what-to-look-out-for,2023-02-20 15:00:24,Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,VTRS,0.262522,-0.028133,Neutral
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later,https://www.fool.com/investing/2023/02/18/3-dirt-cheap-stocks-to-buy-sooner-rather-than-late/,2023-02-18 13:14:00,These pharmaceutical stocks probably won't stay so attractively valued for too much longer.,VTRS,0.376509,0.25295,Somewhat-Bullish
"Biocon recalls 3,665 bottles of antifungal drug in US for failed degradation specifications",https://www.moneycontrol.com/news/world/biocon-recalls-3665-bottles-of-antifungal-drug-in-us-for-failed-degradation-specifications-10115601.html,2023-02-18 07:25:58,"In its latest Enforcement Report, the US health regulator said that the Bengaluru-based firm is recalling 3,665 bottles of Posaconazole Delayed-Release Tablets ( 100 mg, 60-count bottle ) .",VTRS,0.152499,0.0,Neutral
BMO Downgrades Viatris As Its Looks For More Visibility On Next Phase - Viatris  ( NASDAQ:VTRS ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30964067/bmo-downgrades-viatris-as-its-looks-for-more-visibility-on-next-phase,2023-02-17 18:56:48,"BMO Capital Markets has downgraded Viatris Inc VTRS to Market Perform from Outperform and lowered the price estimate to $14 from $16. The analyst writes that Viatris has progressed well with strategic initiatives, but the stock could be rangebound.",VTRS,0.781119,0.636624,Bullish
"NVIDIA To Rally Around Over 30%? Here Are 10 Other Analyst Forecasts For Friday - Axalta Coating Sys  ( NYSE:AXTA ) , Avantax  ( NASDAQ:AVTA ) ",https://www.benzinga.com/news/23/02/30959356/nvidia-to-rally-around-over-30-here-are-10-other-analyst-forecasts-for-friday,2023-02-17 13:30:25,Keybanc boosted the price target for NVIDIA Corporation NVDA from $220 to $280. Keybanc analyst John Vinh maintained an Overweight rating on the stock. NVIDIA shares fell 1.7% to $216.22 in pre-market trading. Needham increased the price target for EPAM Systems Inc EPAM from $400 to $415.,VTRS,0.270773,0.017038,Neutral
Ophthalmic Disease Therapeutics Market Exhibits 6.4% CAGR and to Hit USD 54.87 billion by 2030,https://www.benzinga.com/pressreleases/23/02/g30956403/ophthalmic-disease-therapeutics-market-exhibits-6-4-cagr-and-to-hit-usd-54-87-billion-by-2030,2023-02-17 09:02:28,"Pune, India, Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- The global Ophthalmic Disease Therapeutics Market size was valued at USD 33.56 billion in 2022 and is projected to reach a valuation of USD 35.57 billion in 2023. The market is expected to reach USD 54.87 billion by 2030 with a CAGR of 6.4% during ...",VTRS,0.033328,0.0,Neutral
Gainers & Losers: 10 stocks that moved the most on February 16,https://www.moneycontrol.com/news/photos/business/stocks/gainers-losers-10-stocks-that-moved-the-most-on-february-16-10099061.html,2023-02-16 10:46:46,"Among sectors, information technology, metal and realty were up a percent each even as the market ended flat ...",VTRS,0.05133,-0.031878,Neutral
Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here's what analysts say,https://www.moneycontrol.com/news/business/stocks/biocon-reports-a-consolidated-net-loss-of-rs-42-crore-in-q3-heres-what-analysts-say-10094671.html,2023-02-16 06:14:15,"A one-time loss of Rs 271 crore during the quarter, mainly owing to professional fees paid for the acquisition of the global biosimilars business of American company Viatris, triggered the loss ...",VTRS,0.377142,0.22445,Somewhat-Bullish
"Russia was cut off by Viagra's manufacturer, leaving the Kremlin scrambling to commission generic erection pills",https://africa.businessinsider.com/military-and-defense/russia-was-cut-off-by-viagras-manufacturer-leaving-the-kremlin-scrambling-to/wh2c5lr,2023-02-15 23:35:53,"Russia was cut off by Viagra's manufacturer, leaving the Kremlin ... - Business Insider Africa ...",VTRS,0.416844,-0.253082,Somewhat-Bearish
"Russia was cut off by Viagra's manufacturer, leaving the Kremlin scrambling to commission generic erection pills",https://www.businessinsider.com/russia-cut-off-by-viagras-producer-scrambling-make-erection-pills-2023-2,2023-02-15 23:35:53,"Russia Cut Off by Viagra's Producer, Scrambling to Make Erection Pills - Business Insider ...",VTRS,0.339356,-0.218896,Somewhat-Bearish
Viatris  ( VTRS )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2054818/viatris-vtrs-to-report-q4-earnings-whats-in-the-cards,2023-02-15 17:01:00,"Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.",VTRS,0.580434,0.157741,Somewhat-Bullish
These Are 3 of the Nasdaq's Cheapest Dividend Stocks,https://www.fool.com/investing/2023/02/15/these-are-3-of-the-nasdaqs-cheapest-dividend-stock/,2023-02-15 15:23:00,These stocks can be good options whether you value dividends or growth.,VTRS,0.407844,0.347825,Somewhat-Bullish
"Biocon reports dip in PAT 25 percent yoy; Revenue up 36 percent to Rs. 3,020 Crore in Q3FY23 | The Financial Express",https://www.financialexpress.com/healthcare/news-healthcare/biocon-reports-dip-in-pat-25-percent-yoy-revenue-up-36-percent-to-rs-3020-crore-in-q3fy23/2981625/,2023-02-14 15:21:00,Biocon reports dip in PAT 25 percent yoy. Revenue up 36 percent to ... The Financial Express ...,VTRS,0.109455,0.09613,Neutral
Biocon Biologics update on USFDA's CRL issued to partner Viatris  ( Mylan ) ,https://www.business-standard.com/article/news-cm/biocon-biologics-update-on-usfda-s-crl-issued-to-partner-viatris-mylan-123021300239_1.html,2023-02-13 03:50:00,Biocon Biologics update on USFDAs CRL issued to partner Viatris ... Business Standard ...,VTRS,0.666827,0.159392,Somewhat-Bullish
Biocon says USFDA issues CRL for biologics license application for Bevacizumab,https://www.business-standard.com/article/news-cm/biocon-says-usfda-issues-crl-for-biologics-license-application-for-bevacizumab-123021300100_1.html,2023-02-13 03:02:00,Biocon says USFDA issues CRL for biologics license application for ... Business Standard ...,VTRS,0.331765,0.0,Neutral
3 Healthcare Stocks That Are Too Cheap to Ignore,https://www.fool.com/investing/2023/02/09/3-healthcare-stocks-that-are-too-cheap-to-ignore/,2023-02-09 10:52:00,Pay attention when stocks have these kinds of low valuations.,VTRS,0.348919,0.348962,Somewhat-Bullish
Why Europe's drug shortages may get worse,https://www.reuters.com/business/healthcare-pharmaceuticals/why-europes-drug-shortages-may-get-worse-2023-02-08/,2023-02-08 06:07:33,"[1/4] General view of the Teva Pharmaceuticals plant, in Ulm, Germany, in this undated handout image. Teva Pharmaceuticals/Handout via REUTERS LONDON, Feb 8 ( Reuters ) - When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug company's ...",VTRS,0.026562,0.0,Neutral
Medexus Welcomes Two New Board Members,https://www.benzinga.com/pressreleases/23/02/g30744226/medexus-welcomes-two-new-board-members,2023-02-06 22:00:00,"TORONTO and CHICAGO, Feb. 06, 2023 ( GLOBE NEWSWIRE ) -- Medexus Pharmaceuticals ( Medexus ) MDP MEDXF is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors.",VTRS,0.03792,0.153288,Somewhat-Bullish
Medexus Welcomes Two New Board Members,https://www.globenewswire.com/news-release/2023/02/06/2602543/0/en/Medexus-Welcomes-Two-New-Board-Members.html,2023-02-06 22:00:00,Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus's board of directors ...,VTRS,0.03786,0.158201,Somewhat-Bullish
Biocon sells 9.96% stake in contract research firm Syngene via open market,https://www.business-standard.com/article/companies/biocon-sells-9-96-stake-in-contract-research-firm-syngene-via-open-market-123020101285_1.html,2023-02-01 14:03:00,"Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing ...",VTRS,0.194242,-0.111842,Neutral
India's Biocon sells 10% stake in Syngene via open market - filing,https://www.reuters.com/markets/deals/indias-biocon-sells-10-stake-syngene-via-open-market-filing-2023-02-01/,2023-02-01 13:16:00,"BENGALURU, Feb 1 ( Reuters ) - Indian biopharma company Biocon ( BION.NS ) sold a 9.96% stake in its unit and contract research firm Syngene International through open market sale, it said in an exchange filing on Wednesday.",VTRS,0.186738,-0.104203,Neutral
"With 8.9% CAGR, Opioid Use Disorder Market Size to Surpass USD 5.64 billion by 2029",https://www.benzinga.com/pressreleases/23/02/g30661582/with-8-9-cagr-opioid-use-disorder-market-size-to-surpass-usd-5-64-billion-by-2029,2023-02-01 09:30:18,"Pune, India, Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- The global Opioid Use Disorder ( OUD ) market size was valued at USD 2.88 billion in 2021. The market is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2029, exhibiting a CAGR of 8.9% during the forecast period.",VTRS,0.040212,0.0,Neutral
Stock Upgrades: Viatris Shows Rising Relative Strength,https://www.investors.com/ibd-data-stories/stock-upgrades-viatris-shows-rising-relative-strength-2/,2023-01-30 08:00:00,"One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Viatris ( VTRS ) now clears that threshold, with a jump from 77 to 81 Monday. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.",VTRS,0.585687,0.252176,Somewhat-Bullish
2 Superb Dividend Stocks to Buy Today and Hold Forever,https://www.fool.com/investing/2023/01/24/superb-dividend-stocks-buy-today-hold-forever/,2023-01-24 10:36:00,These two companies have long runways for growth and decent yields today.,VTRS,0.351392,0.160305,Somewhat-Bullish
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors,https://www.globenewswire.com/news-release/2023/01/23/2593139/0/en/Aerovate-Therapeutics-Appoints-Donald-Santel-To-Its-Board-of-Directors.html,2023-01-23 13:00:00,"WALTHAM, Mass., Jan. 23, 2023 ( GLOBE NEWSWIRE ) -- Aerovate Therapeutics, Inc. ( Nasdaq: AVTE ) , a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald ...",VTRS,0.041755,0.016421,Neutral
Yellen pushes for China to address Zambia's big debt burden,https://apnews.com/article/china-government-united-states-janet-yellen-kenneth-kaunda-africa-63f4a0098fc3b2d14016e0f388b0ae6c,2023-01-23 12:56:15,"LUSAKA, Zambia ( AP ) - U.S. Treasury Secretary Janet Yellen , on the second leg of an African tour aimed at promoting American investment and ties, said on Monday it's crucial to immediately address Zambia's heavy debt burden with China.",VTRS,0.060236,0.068,Neutral
3 Dividend Stocks That Are Ridiculously Cheap Right Now,https://www.fool.com/investing/2023/01/20/3-dividend-stocks-ridiculously-cheap-right-now/,2023-01-20 10:52:00,Their valuations are low and their yields are high.,VTRS,0.256314,0.418401,Bullish
Deloitte's CFO Program Names Frank D'Amelio as CFO-in-Residence,https://www.prnewswire.com/news-releases/deloittes-cfo-program-names-frank-damelio-as-cfo-in-residence-301724411.html,2023-01-18 13:02:00,"NEW YORK, Jan. 18, 2023 /PRNewswire/ -- Deloitte announced today that Frank D'Amelio, former executive vice president and chief financial officer at Pfizer Inc., has been appointed independent senior advisor, U.S.",VTRS,0.049526,0.068628,Neutral
Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?,https://www.zacks.com/stock/news/2039890/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe,2023-01-17 11:20:07,Sector ETF report for ...,VTRS,0.13459,0.070304,Neutral
Could This New Drug Launch Be a Hit for Viatris?,https://www.fool.com/investing/2023/01/12/could-this-new-drug-launch-be-a-hit-for-viatris/,2023-01-12 13:00:00,Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.,VTRS,0.685631,0.257874,Somewhat-Bullish
"Jefferies sees big pharma firms getting bigger, lists Sun Pharma, Syngene as top picks",https://www.moneycontrol.com/news/business/stocks/jefferies-sees-big-pharma-firms-getting-bigger-lists-sun-pharma-syngene-as-top-picks-9845211.html,2023-01-11 05:06:30,The USD 27 billion domestic pharma industry has structural growth drivers in place and well-placed to achieve low double-digit growth in the coming years.,VTRS,0.047559,0.039727,Neutral
"Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets",https://www.prnewswire.com/news-releases/theravance-biopharma-inc-highlights-2022-accomplishments-and-2023-key-targets-301716180.html,2023-01-09 11:00:00,"Theravance Biopharma, Inc. Highlights 2022 Accomplishments and ... PR ...",VTRS,0.025651,0.070654,Neutral
Is Now the Time to Buy 3 of the S&P 500's Cheapest Stocks?,https://www.fool.com/investing/2023/01/04/now-time-buy-the-sp-500-cheapest-stocks/,2023-01-04 10:05:00,All of these stocks are trading at less than 7 times their future profits.,VTRS,0.385137,0.018979,Neutral
"Global Biosimilar Market to Gather $83,836.40 Million by 2028, Growing at a CAGR of 24.90% in the 2021-2028 Timeframe [170-Pages] | Issued by Research Dive",https://www.benzinga.com/pressreleases/23/01/g30257179/global-biosimilar-market-to-gather-83-836-40-million-by-2028-growing-at-a-cagr-of-24-90-in-the-202,2023-01-03 14:02:00,"New York, USA, Jan. 03, 2023 ( GLOBE NEWSWIRE ) -- According to the latest report published by Research Dive, the global biosimilar market is expected to gather a revenue of $83,836.40 million by 2028, growing at a healthy CAGR of 24.90% in the 2021-2028 timeframe.",VTRS,0.121959,0.215258,Somewhat-Bullish
"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division",https://www.prnewswire.com/news-releases/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-301712041.html,2023-01-03 14:00:00,Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life ... PR ...,VTRS,0.725395,0.352728,Bullish
Could This Drug News Give a Lift to Eli Lilly Stock?,https://www.fool.com/investing/2023/01/01/could-this-drug-news-give-lift-to-eli-lilly-stock/,2023-01-01 16:00:00,"In November, Eli Lilly received positive news from the U.S. Food and Drug Administration.",VTRS,0.201803,0.0419,Neutral
